var title_f5_9_5264="Normal upper GI series";
var content_f5_9_5264=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal upper GI series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal air-contrast upper gastrointestinal study showing normal gastric folds and small intestinal anatomy, and no masses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_9_5264=[""].join("\n");
var outline_f5_9_5264=null;
var title_f5_9_5265="Furazolidone: International drug information";
var content_f5_9_5265=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Furazolidone: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11372047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Furoxil (VE);",
"     </li>",
"     <li>",
"      Furoxone (IN, PH);",
"     </li>",
"     <li>",
"      Giardil (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F11372048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiprotozoal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F11372049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms",
"     <i>",
"      Giardia lamblia",
"     </i>",
"     and",
"     <i>",
"      Vibrio cholerae",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F11372051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Diarrhea/enteritis: Oral: 100 mg 4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F11372052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 100 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16449 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-BFBE39938F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_9_5265=[""].join("\n");
var outline_f5_9_5265=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11372047\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11372048\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11372049\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11372051\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821255\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11372052\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/16449\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/16449|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_9_5266="Unstable midshaft fracture";
var content_f5_9_5266=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unstable midshaft fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 303px; height: 478px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Twelve-year-old girl with midshaft both-bone complete forearm fracture. (A) AP and lateral injury x-rays. (B) Two-month follow-up xrays. (C) Six-month follow-up x-rays (ulnar nail removed).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mehlman CT, Wall EJ. Injuries to the shafts of the radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_9_5266=[""].join("\n");
var outline_f5_9_5266=null;
var title_f5_9_5267="Circinate balanitis";
var content_f5_9_5267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circinate balanitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Circinate balanitis characterized by shallow ulcers on the glans penis and the shaft of the penis (arrows). The lesions are generally asymptomatic.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Professor Victor Newcomer, UCLA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_9_5267=[""].join("\n");
var outline_f5_9_5267=null;
var title_f5_9_5268="PTC before hepaticojejunostomy";
var content_f5_9_5268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69335%7EGAST%2F56602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69335%7EGAST%2F56602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complete transection of the common bile duct after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 234px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADqAYYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwChoKxWOoR3JbaIwqkddx9PrXpULFIhNIP378/7orz7QYxe3uGTCJ8/sSO5rvfM3xI56MobA7YoAztSGyQNn5TySe/oKxZpFEjq4GzHPPX/APVW1cnejIxPPc9PasC6cbmClVKjp6Y6mgCcOzOVIXYRwPXtn6VLa7m3xEhpETaGzncP8R0NZLXAiZkEqncuEz198VotmNFWJuQcoe9AEWu28k2mTRxeYjqQ6mNsEY6803TTH9kjEYxLn95z0J6k+1W3uohAXnx6PGeSa5WD7Tb6hJGC32dyec/Mw+tAG0l7HbPJEDuljf8AeoPTsw9qr39+JIGM7hIjwqIOT6f/AK6qTWoneMlzEycbk6svdT7Vm27+Zqy29yqssWY1Bz1HQ0AWdOaRrR3kifcJOCx6g/561OZSDtTnf0xU3mmRAruoAB2qxxx61CHj87ZGfMnx90GgBqRYkZt2QeSAcA+9JdI811bRO5hjdiDg/ex3qxIEjVXYhUXqz8Vn6he281uqxTAyqwKkD9KAOlt1CMAqqEHGxRk/WoLycIY08wbj0H93/CqGmXM93GnluqEDa856HB70hkEt0oQK6AkPIRyfegDoNN81UDPjaD9zJrVRFdlOeemPb2qjYhxH82CCcKfQVrwfIq4xkc5oAlgjDPgoSV4watbNsmcgcdDVWF2Em9m+TdgY46+tWWb+IDHNAGhbMhVQzFgO4rc0uRI2RQp4PXrxXOWxAznnnNatsSGRtwAK9s0Adhayrv7itAEHOOlYNjMCip/F65rVs5g64xQBZcHa20AtjpVN1ZS27JB4x/dq9TCA2KAMK5nDIVyMgHrxWTcMDGuey5U/zyK3dSiiZJGdSsg7r3rl7jzYosyg7c9cdqAMHxEpmsmj3AZYbT265z+Ncbc2B86R45AsL9iMtmup1acTTEDbjqB3/wAmsl4A7EHcMDJYenpQBnqqmPaqjywuMKPU9qVrdXhnYtg7gRxV51APzZ2MRtGe9OCEqMKpUjByKAMHU7dQD5bMxU7lGMbvWqUluGHyjhyMexFbt5GFY8FY8dSc5HtUFvbrJJ8xypXoe/8AhQBm6lZrdWzKw+UqFyPUd6xbG3uY7lhIDlQRuzwR2xXZvCPLOBxyCvX/APVVFLYeYuwjaDgd/rmgCxFJuhj8xgxKDnvj1NVrlXALA5j67X7VciVYXZAAI+oz2+hqC6AZ9pGSMZJoAxrgqFJYlazJgGJ3EdchjxWzPauSzSsFBOQO9QpbRKPlU7z1J5oAzkik4BQNk/KfStCBNrYwuenFTKmBheF9SKlgjTB5Ptx6UAKseQ20AHPfpTZUAyUPPQgVMEAOAdoI79RTJBg5UHnGeOtAFG4JGQwHT6isy6RDgggfh0rXeNipJ49M1ntBuGEIAJ9aAMC+tUkJdlQ8d+1ZE1oRGdrHd6V1M8BAJ28Z4PXmqjwBsgjgZ/OgDlhFIvDKSfSiugntQiAJjOec96KAPSfC9v8AZrISH702efSumhJktCBy8bH8jVA2yQiNF6KgTn9at6e226dW58xcAe4oAhnOC3Pvk9vpWfexqZQzAbHGG46H2rSvI3Ew25Cnp78VkX9/HCDE2Np+UuegoAzdQWNLaYXO0IVz83VfxrM07UZ2tQ0BEgB272OCR2OPWrEw84fvGEqnoc5DD1rFubWe1V3smLoeoAGf/r0AaB1GCPcWLsw4zt61BBqsFxqAiAzhgvuD2qnYzxXQeO4iUTkEgrwHPf8AGsHxNE4nRrFlTEiuoTjOR60AegsHUHLAnGCSORWHrZFvewyxk4kXcx7gjrWja3gltI3klZm2AOueSe4+tY+s3ifaJLSeJi6kOHDc9OM/hQBcspUvYS0USnaxBY8/hRdzRWUwDRBXdcgKcBfcn3qjo+pQ6VpM81xyEk4Xu4x2rCutcj1IzOUkWWTpIMfIe2RQBq3V9dXd9HEyK0bfLEF5G761o/2Sixk3U4VsfMq9qxrbRdUtNJN7bbTcwyiSKEnJde7Y9utdzoCyahpsdzfwxrcSE5yMZ9x6ZoAyLV5F0s2Qj+QnII7j/arY03TmRBLP8qj7qZ6VqzQocrGAuODgdeOmaeFYoFJ424Az1oAt2zgxpxyOCMf57VajyVLLgNjPFU4AUO3p0yParUeACN2eM59aALY+ZcbWycAH3qyrBo8EnPTmoYhgDGRxnnrUqRr5mGIGeAaALUanGAOOMH+latmB5a+vTms+BCBk7vl44NaUKrkBS3HTnqOtAGnaybHCnAJHFbMLHdwAU4/CsCIZBDkH0Iq/b3ZAZQhPOST3HagDo0JIyRTJCqnLMAOvNV4JjIFbAA7c9TTbqRTGd+ODjaaAKOrOrA7PvDvmsHWJ82rRr98KQwPY+oq7cSl1II/2gfasa8VZTISck+/b1oA5HzU3ZkwckjHpUe8LkgZyvOO1JrOm3qXu5JECNgh16kehHY0xNJRw26aZzjoXxQA27kSMZkYKpxhs8AimG7tim0yKp9AevepE0a2M6xyF2HU7nJ5rUtdLt0AZYYgckYx1H9aAOcvbiDbhZVYFsHB6fhS6bPD5XytGSWIYk/yrbutJtAd62iYA6ZyCfeqenaPZyQKTbhTk4+Y+tAFWNvvq2GOeNp4zng1RuJDA7Bjgg7gO1WJNMg+1SCIsqtnCg5AqhPYMrqFvHKjkqy8n6GgC40nnRgxqGQ85z0PpS2xYlgE7Y3HvVMFrcL5ZPXoR1P0rTtgJI/NChXY5K+lAGVdgljhWLH+8KrsozgHPcE9RV+5VvPAz94Z9s1A2DnuB6dqAE8tnUMvcZOe1EEDk8Dg9Oehp27BATIPTnnNXLKRCFUjBB5I6fWgAigw244bjGcUyZOflB2989K0kUbW2kbT1x2qGdMD5c8/5zQBhzKFRgSBzx6/SsuU+W7Kiltx4PTBrYu1OCGx8vHXpVSOI43dfcjvQBlyRs2xU5I+8G7GnXEUYVcsA57VYKE3HQdfm9verFzGrLh1Bx3/rQBz8x2ybShBHqKKvXMQyF5OO/p7UUAepXsZExzwpH5Gq+4o4ZSdyHcDjGPWte9gIYk9x+lYeoysUkgjJJ5DsB1H92gB+rTeeWiiAA253nv8AT2rnLpccMglXpsxnJNa9o4nijySXCFCp7EHp+VMmhUFnIHlnqB2P+FAHOnSomhMaFhjkKpwD7VUlsijBoGaMg4wTnP4V1DwYfAAz2z/DWPrNnLKGmg5ZRtdh0H0oA5HVRNFciZo/LkU4GOA3vUWp2wu3t7m3BELDDcc7x1H9a6C6W3k0147qTy2j/eCUjJJH8P41x19q0lzB9ms90UUbmQDoWOOTmgDW/tSxtdJ8mJxLfAk7QMhB/e+tcnrOpvJIEV2Lnlznn2rNleS1kE/llwCcHoG/Gr2noszvdTBSzcDaMiPPb3oAe1vcSW8UEZaRmbexPIxirelWX2TMrR+awYHYTwcVtWWmPDos125GxXWFAB69c1ViYhxgc+gxQB6bZRCSKG5MeHlUOV4+QkdKuDIJKkfTHArL8N3kl/p8RkRAIP3TsAeT2P5VsYJUAHr3x15oAdGAseFIIzkH0qQgEknBweOKACTgnB7kVLGcD+YxQAsXL+471MEXDDAyOR/+qkiGDu3Zz2/wqyifKDzkHOe9AE0QwBxnHGc9BVlAOCFwOv0pigAZJx6jvilNwQ2Ixn0PrQBoREKUBORj8qtCQjbjAHc+1ZMZYgk/MRyOelWlywZi2R1/xoA0IZAGKt1PUmr0FwBvclcjqe9Yik/IFBwx9evtVmHALAjJ7nNAG7HdDBbDDHOB/SknuiyBSwwSBg9ayvOMYBPbsTyaRptyNyAR1HXFAD712wQDtPYqf51XlIwJG24UEGo1uojCSW3MWPCj9KhlZ5D+8Ro0cdBz2oAydTu42tlkdAqAffYdPcisCPVmjmIwpjY7d49u4rYuwHswuQwB2sOveoZLFDbv5SKsi5IGOOOtAFaG8LFiZDxyi7eQKuG/KxD5ZWYHAAXp70QuRErg8soPqatwKCc4Z2z16UAYV9rJZlgRZmZm+Zth6fSqHh/VJZLV4ds7SKzbRtxkZ6Vp6yv2XW1IB+W3LIT/ABH0+tQaLapbwQync0kpLHt19KAM/Uru/to0kjiJZhn5lx+GaoW11emULcRoyO2/AU5545rqbm33zWqHozHg+lQarbKGjZF2urbTt/ioArTwKgjl3AjpnuPalkj8sYJLPjOAaneE7cbSUbB645Heqcsc6S/uwEzngc7h6UARzqAwLqAB065qDy9xJYDnq2OCaQfa9zhSHfpkj5aIzdGYRXELAA/eXjn3oAb5bggbgQOQAOoq/Z7MEEDjoMVGEUk4Q4IyM9vpWnZWykMRkgDGPQ0AQtui+8uOfSq0s0i43Bdo6e/4+lac0WFKg7gR9aosm2TYOT1G7tQBRESSsdzFWPY96V7VcHnAI5q+tsCpyBk9jyCKozIY8iNivb1oAyUgImZkG5ehNT3KqyllBDYwc1dtmChlkUg5zkD9afcWwmgZoyNyjIP/ANagDnngBk3Y5I6iitm1sWZ2Lg5ooA9D8Rn7IWhU/vSxUZP3R61zJjdnB3HJ5P8AjXU+Ikaa8d3BJdQSPTHpXOTowR/s4LS4+X0oAwZZb5dSW5iMYto3Iyq/61sdK0pZJNQsJfs+LebGdzDOQDyPxq9sEUaKMFgMqo/vetSNpk02y7iYKxH+qPHP+e1AGNDcS3ECm9hMKtnDIPvU2XTpTcgwTjysbjhucHrxU0+n3nmpNdjhHyApzj3qyGtrxxbwI0c55OeM0AcJ4r06SPTLgDkhgx5xkZ61yOnC1g1GOW5iVwvLKW4B/rXpniS2sp9MuoorqQ3SoQNq/eI5xXjP2hLaTe77gBkoVxQBq+PtPeyWA+UYbeUl4gvTa3IP9K5XTJJ7e5WVApQ/fUtwR6fWup1zxAut6Bb288e2S0OI5Af4D2+lcoW2sMcnjBz/AFoA9xshY694PZdOjEcOw7Ymb5o5F5IJ7muEH7uTkbz6Diui+EcjS6dqSAg4kRgD64Iz9KwL6MwXcqSPuO4ghRxnPagDuPBV9H/Z01tsJaIGVcfxDuK6eNfMiBwQz4OAelebeDrsWuqOzkMvkvkE/e46V0llf3d2QsUkm4L/AKtRjaB6CgDrQuGBxwPzp0att4H61TSaUxI0yHAABwOc/SoLuWeIq6sDgkgL3oA1yUXA45PGD1p3mtn5BgDjOaoWt0kig7QpHQdjV6IYA4Ygd/WgBVzkEnJHUetTbsKMsdnt1NNwpYY6Yzg9qkjHDBRz2oAsqcAZ6f0qX7QIx8x5zxgc/lUNtHI21Sdp6FvStK3hhgxhMserk5OfSgCvB5rKFWFzznLDFWwpQhnDDGSe9SiUsTnHsc9qlUnB6f8A1qAIosuN7cAjgmp45vLYLgAtwfX/APVUcxYOCuOMADFMXO5iOuM5zQA9rdTK+08npgU6OERqNx+Xp9aSIkbV2nd1/ClkkC7uoHTp3oA5nVGW3klQqSu/OR3qJ5thYq2MDOFPB45/Gp/EHlXE8iA/vEwDxgnvg1z0rT+WyRZV34z2z6EUAXLZy9pGgXPGQfarkE2VBBPQAc8iqdu2BhhhgApA7e9W4wXi2gjPQjqKAI9QaO8tirMROjfIfbFVYcHbtHAHT2Hf86seRiRgGC45BHHXtR9nKyHO5Rt/vcCgCvJI63FrOzLs3bSuemas3Kgm3iHXzOwzketVLgLKpiADO33QRwMd6hht7tpliMjEb87s4C+3rQBuLCGJ2MpA+XkYzVG4t8LwF29wB3rZtUcxuGUcscgjpUF2hjJOCRjkgf5zQBibACQq8H7o6VG8IMgyDlujDmrMgUYZGwOuCasJH5hOdp77c0AVktmOduCR/nmtnT7E/Zt7gg7s8dRTIolTGV5OefetrT1H2Ycd+hoAyJtKD73hcq3fcOtVDYSKGaYZHr1FdLJHthIwDz+lOEIClOq5zz1oA5RrYZLAnHQZ7VnzWhMpBGVXnpXXXtrCyFQDk56dqz5LABf3coGRwG5oA59oFQkFeTwDUBhbyWYfL6Z71qynyFKTQsMHO7qKoz3ab8AKoxkZoAfa5XHmKGO3rRWc93NvIB2gdGHeigD0jV0LRiQdVJBA7A1hyRGN3yp68Lnqa6qZA0ThhjdwT6HtWE8E8WZ/J3sAcD/PegCnBZMk/nT4DjhAOcD396kafyZfIRSzydM/wmp57hCi+SweVwMKedppsFqIizy5Mjcsc9KAIZrGWfPmOUOCoxzg1k39u9pbPcXgAWIYZ15rp4v3kfJ+dep9R61Qv4RdyLbDmLq57GgDm7ZYJLfzreLziGyJG6j2xXl/jnQ7a31S5wGRXPmRMp6A9R+ea91jhSNVjWNVQDG1RjIrzX4lWPlWtmJUOwSMIpc8NuH3frQB45bReS0kLfKWXb04NC2hjkHygnrhu1bSwAuqyruVT0J5z6Vo32n+aA6ZWNuAR3OKANT4WShdc+zAEPLC7MFPDAc0njC3+za9dZXBZhIoU8lWGeKoeHJH0XURdIV8wfKSR1B+8PxFdf4/tYrrTba/tEEcYAXPUlWHGaAOFtZD5mWzx0AB+X0z716fpluLW3ik2tJclR5nzYxn2rzK08uOZC3zkYIxxn6+tekaFeDUtOS5YqXBKyYGBnsaANeJ5WPJ4Uc59Pr7VOgbnaOOw7VFEpbGOnAK461aiUKRgYx0oAI7ZM7vLHXpnjNTRHcSFB4PGfWpI4WcDeAgzwp6irMSLCu4nHsO/wD9agBscW75mOFPGKtwx5OVyFxnp1psEiOpKY+VtoOKflmYYIC5IIPUigC1GygAAYUfmakVgTkEAnjPY1WBA6fn1pwOSCOuKALCt8vTjpipFk7AHP8AIVVbJIOcj24qRQMgZ5xx7UAXFIb5STjpyaliiV8E5GRg46fWqseFDEnnAzzU8TdB0Pc0APNpISAkmcce9MuAY1DTcKFzuA9KtKxYEA4xVLWRiwwTyzYHNAGBdZmcsxG4tuOeMVTKLHuXjrlc4pt7dKpyGVWyACaqO27IVmOTgELmgC4VjS438FGXAOc1OI0C5DDHUgCs9/M2KdkjgDBGMVJGLt1Gy1IIOTlgOPWgCzJKEkZS2cDHK/doUoWUu+DjqP5VSuIrzyyZIAnHzLnJJq5bw3Udou6Elx09qAHwW+7dI4XcxPUdR6UjqS3K46bt3t2pv+mBQ5gJB6LnOKie4dcb4JoyDkH7w/OgC/ZSGN/LOWB7k/lWo1scHzw3A6Y71jaZJvkJUfL06/yrfadnRQQwIGMk9aAKDW0KsSI0z3G3NAhVCQEUY9BVhiww2AcelSIm8L78Y96AK6w7sHjAPXvWrbxbIIgQuccVDHEAo468VrC3/cIMchRjnpQBRwFyxB5FV5H7cD3q1KDjBB+nrVG43Bjx+VAFeSUsWzxjvVF5sIwHVfXpS6jeRWqkNyT2WsG6vZpQFhG3PQnvQBeuZw8aq2Bn1rndTjAk3RkdegPerKI7jJZyPekESIjDaSB3oAyDd7JCrAoR1z0oq1Pbk8lQwPPIooA9ntLU3UhZx+5jOfqfSk1GMrICqkBucjtW4sKw26xJ/DVC9iEkRA4I6exoA5dbOGGRnRAZG6v71DNtQZJJJOAPU+1acsYAweDnoaqSovpnP6UAZ4jJcEu+4HgDgH2q1sRFwgOw8jPX6GkwOSe+c4pyErlhkgn5h60AV5dvGAzdyAKyde01dZ0i8tJV2o0ZZCV+YSAZUiugbBGQ2Qe47VWnKRrlzgEdD3oA+cfKMalX3l1JV9wxkjrXYaJanV/COox20Ze6tJVkTPO4EfMPrV3x/o1umpG7EbQx3IBIU8Fh1z71z2m6nPpkymzcw7fmH/1/XNAGcsJdyzMzHvx0rom1aK58PtplzG+UT93MORxzhh/Wo9SeHVGNzaxiGZ/9bEvClu5X0BrAdzFIpBOR29aAMu4JRhIrZVj8rAcYNbHh3ULvTboG2Yht2ShGVYe4rJnP2ecvGu6GTlkPT/8AXWlYFLiNDCTgDJXoV+tAHrOnTpf2cV3DxHIOFz0PcVoxKsbADJPSuT8EzPDdpbM2IpAQQfXsRXa7FUcAZxQAkasH7biKVyzEYPJ7UnIJB4BGNw7VKig89/8APNADVHVgD+faplAwTxkc0xFwcjJ9acjYALZBPX2oAmC8AjGR09KcRxnjB6etMXPcH1+lOH6570ASLgY4H4dzUiNt+U9PYVC0iR53H9etR/aiAQqj0I60AacQAPHGOaeCF5Lbf8ayXvpM7YlVTjrmmwyFp8yMzNjOc0AbkNzEWHzrk8HIxTdUQTWzJKpIz/D69jVDerYZfbg1Yhm/dFZeQOUBPUUAc7JZrERnLMedxAzTkZCQWcgjIPGKNbmlSFnGXJOAqnr9K5u6e4RwxiTDckMxOaAOiW52kpK4Ck4ycGr/AJq84kULxzjpXJIJWuEKqTj5sjGMelapnuUjD7Iyd2SM8mgCzqLRlWLzDJB69xWjZTRvZIRKCwXHXqK5u5uZ5tVhSS2iVMHJLcE49areHby6NrJHmMKrMoz9cdaAOnjnzHhmTA465qLzI2faDGcemMViXdtcR7mcxqsnyqV9aINEBRfNcBgDlVH86AOotIgSOFXn0rReMAAIBgDoRWDo0htYI1I3D7pGc1r3MxdAiA7z19qAIZZUUjGMZ7VYhljLYb5f61T2ZbJ6k4HFW1VUBDKe5HFAGhHtccMCB29a2GUbF7EAdO1YFrEpYjbxweeK0pGMShg5CAd+1ACXW1FZjjavX2rmdTvZHZo7fBX+8ak1bVWkOxD8h74/nWeksZGxTgjigDNlj3tl8kjnPeoJCOmOlaVwgI+YcjjIqpJEc5Ujp0oAqk7QNqH86il3FGZsAkY+tTlSoyRjPBFVG3N8p9e/SgBqscDCliOMA8iipII9rngnIooA93Y7kRs5DKOlVpV68YPb3p8BH2fB6ISD7CmE70Rl5B6EenrQBkX0RDCQdOh+vrWfIm0HGM+/St2XkHIzkcisi5jKSEZ47e9AGdIpAycYzzio27kc7eufT2qxL8gZmcge4rKuLnLEMQI+x9/egCaS4C8Iw3dznqKq7g+WBznnntVO4uJ1UmCEXG3qR/Kiyv4btykQKzBdzqwxigBuqWEWpWMtrKBhhlHP8DdjXkOv2Euk3DQ3ihGBxxkg+4PpXtJUyMNpCr/FjqK868ZQ3eorNbTlvPgOUyMf5BFAHKWt2YZA2BtxyD3rT1GxW8the25+XjzUzyD6j2NYFjnJSYZkBwPw7fWtW0vWt3IGWU9RQBz2sRtHHFgYAYg+1VrKeWCUPGxVlOQR0rsdS0warpclxZxhpIlMrqOTgdTXHRr5afMhZGxhqAPQvCetWX2qGW7JjaM52D+I+ozXp0bxyxxzRuJIXXKuOd1fPMBKsFOSRXofgDV5Le5Synf/AEachQD1VuzCgD0Q/eBBA7/UU9mGD+nFUbm5S2bL5beTkdcCpVlJGUBZCP4v50ATOQRg88Y/+vUNzNJAVEMZLHvTyJGkU7gqYxgd6ZI6xtkyOzZztyODQA+2kdUkMzYI5IPapjdqV/csGyOuaoM7sAmQqKchcf1p6nC5Xg9SBQBO0rAgA4/mfekiOSckk98d6ruwz94g4zkngGo1udzgRbmxyx/oKAL4IORjOeBTQ3I8otuByMcfjUBhvHXEQVc9zzTha3H3AzsR95jgfgKANKOZgQzbQcc064uFYAA/Jjk5rMljnCj9yxAHRT2pYbcyR7Q/HoOx/pQBDcfvDhiSM7eOop/2dWjKMmRjGB1qKdXQo2cjf1PUZq2qEYxkk54zQBStUEK44JBwG6DFT+UXc7MqP4Rjp7ZqnbXKywk/d+c9R71bgkyQemR9KAKt1thuiXXaFO8ZPAGMVV0S2ZYEYjauSSO5JOc1oXwEsEu87ZVyuc4BU0+L5LFOgYDJx3oAlmjWSOHK/KGGcntVyZVVHXHGPX9KqyybrYlcFlIIJq5Oy+QXBBBXJoAr2a7WUMB7+9WS6gBt2GXn3qCFVcQ8kKy9fXFWnicAsqYPoB0oAia5LYZT7E4qwknmKUDDdwwPY+1V2s7hwGJRO2Cc1M2nTkLIkuGXkY9PpQBqWDh1J7jqKi1a+wPIib6kVVczWlubhAZAeCB29xWTJch2beGLNzkDI/OgBJwMkBTk9fQVVmVlwccrxkVOXCYy2VxzxUDMGUsp49jQBF9qdAykFlPbvUyPHLGHTGT1B61BNGDkEHnnI7VWdGJ7qfUetAF7y1bHGB1xUEluN3ycZPGOv0piXMigLJhyeMjrW7plp5g8wgFuoBHSgDOgsHVdxXk/3qK6JkGAHODRQB2tscu69nXP4jtVfzVhKxfwSHCA8FT6H2qYHaEf+6cmk1CKOaFlYgE8q3dT2NAENzlQTgs3cDrWfelAjb26A7frTItWinizJJEJl+VgWHJHesu6voSTuuIyfrQBUupGlbB7HGM9KpyFVBZioUDJLHrSapqltBAXBd5cfIiRklq528uZr0eYLa4YMccjAH59qANSTWLBDh5gqjuF4qB2imlFxZTxPKPmYIcMR9K5C+hvDIQlkwHXLN0H4VUtftcLCRXt1lB4kGcg0Ael27meESE7VPJAGDmn6npdpq1sIbpGwpysifeQ/wCFcQNf1IZU3a4I3EJEBkge9MbxTeqFBuywPByAP5UAUPEvhi5trhmaEhhnZKOElA757GuTuWCuTuVTwTlutdZr179utUZzLIHUH5pSQCO4FYVppclwHEcAPlqXJC/dGM8+1AEOkaw9jcxyQSnzAeqDrWJq8wa/kDRr5TkugQbcZOeK07i2dSu0Lg/Mu3oRVG+tvtMBAUmRQdh7/SgCvbXUQIyCCe/WrltdsChjZi275SD3rn4wXbGCpPYdauQsY2wCDzkGgD2TRNZj8T2JWZlivrcfMq8CYAc4966C3x9mi38ADH1rwy21N7B0kiJWUMCpB5GK9V8Na3DrNmUbK3SqWkjzwfcf4dqANuSZY921iF6H3/Co0fceBjnoajCEtuCj2LcY4p4AAxn8TQBKfmPJ9ACTSPKVwVHzDgZoggeXAQbQOpP8xV+C3WHGRubqD1IoArQ2MkxDXfyoeietWXube0XaFxjtjJpmp3QtbN5P4jwBXDXmosZSwcjPvQB31vqUTkJ2PBANWlkRUyp+UnH0968vg12S3IIKkZxyOlbNh4muvM2t5TR9Pu9R3xQB2qyAt8p5/lUwYbhng59OTXP2WsQT3KBkMUjfKTnIP+FactyhIMRBf7uPf1oAoajKkYDSYU78Fs8c1E9+qAhWDFflz9abOvmFkJZkORkDpVVbNFIDbmCgfebp9PU0AWbfakQUE4b72e31qUKdmU6nrtNREfKMLlcYHNSKwG5W74waAELl4XRuGPtwT6VKqfKmQN3Xn+VQnDSYDk8/dx6e1PiYM7c/eb8KALQcBepIHXNV5LloSEbOB3z1BqeXahVlJ2t13GlKLInzckrkf7OKAI7G6WSAx42mLO0n0roreUSQpIhB3KMN6fUVz6R5w+VQE9K0tPl2p5OCdoyuDzj0oA0Mrk7lz2yKtwkHAXLHg1TWKdvmCkBujZ5H4Vds2MZKspVsdCMZoAqSpPHO2FIQ9V7GgQKinau0PyRV0nOWHTdVds7jhvwoAzpIFbPqO9ULjTVLF4yFPXjrW3sJJOMc8+1RsnPUZ9KAObdHQgTL0P3h3ppiwDkjGa6IRB12su5R61n3FgQ3+j9P+eZ/pQBn2VqjSMzD7p479a2ozhfkOCCOQKhtLfyhnn5ua0IvLA9OaAK8srEfMoBzRReMkRXO0k88c0UAdb9jiIG4yEE9S1Eq2yR4EO+Qcck4p8s3lIcHLEcVQ80iQ5PytjJ96AOE1S80zStQlsbiaJr+VxLGqLuKA+1dOjQ7EdXjbKjJAGBxWHqfhXT73xMut+XIt4xwMH5dwGN2KnSKWxkxIhAOSWxkGgDFa4mv7hmcGNy5ULnjAPb2rYtdOaKIlzlSfm471FokHmak8vlsYE+6T0Y+1dIVAB6UAZPluqbdwVduMBeKpTaZZzB45reMKeQVGGU/WtedCpOACp/Sqjg9elAHNjwvZqWzLN97gDHSs6/8GpLMXtLlQhO5o5V7+xFdmefvEeh4qJwdp6ZxQBgL4ZtBboss8zyKfvKAB7jFaMem20Vm9vYgQo4+c/eLD0NWXbHqe1IA7HcTs9NtAGVL4b0v7HFA8BxGDhkO0k1gWvhOxuZmDtdQYOV6EH2ruc9fWkdhjLMBzn0oA8T8Z+EptGvHlhfzbST545NpB91PuK5WRHikRj1xjIPSvoPUPK1Czls5lzbyDBwOQexHoa8T8SaXNpt/LBKRlDwwHVexFAGEXbzSzYznoOcVu+HdWm07Ube5j52NuZT/ABDuPyrDVDuJZTtHPHf8angBLgDgluvf6UAe7wXEN1BHPbsTDKNy+vPb61aji4+fk9hjrXG/Da/Do2mzH5gGliPp6rXeKVUAjPzY5oAenyAjj1Pt9aer529M44NMJBDY/E5p+chsUAYni9iun25ByPMIxXBXLljn5sdC3QV6V4hh+0aPNGxVZuGhDHGXHb8a8ivGnMribcH6FW4x7UASS7t4HIUnnPP61o6Qxyq47YB7HmsizeTzAn3lJztPIJrv/CumwXlwWnh3Koy2DjHtQBb0xTvTYn7w84Arp7iyiMBmkO1sgn2qe1t44BiGEJz1HP61bZg/3sHI+YHoaAOPecQybdwIzhmPelMhYgKsrHpwKu3NtCl3IFRFyxI4z+HtTUTGCGGc46dTQBSkncZHlMp5Iz3qESXLfNHA7euSBitedl8obmVi3BzxUduI2hxuUN90kZoAx2a8WRF8hAAO8nOatW0d8AG2wn1y2cUssS3GoIm/GEPIPHPrUulSRsCrTYKuUz6kUASrFds2SYjt689DUrpcoD5jxjPuasNLDHNlpFO7rg1K0qFcjZt789fegDPjjuS4DRg56lTkmug0a2eNhLLGFOMKT1waoW7lnODx3rej+4FJI+XjjNAFj3U8/wBaZKeoOc0qn5Qe/rTZl3DAP0yKAAA5x14pHQnjt64p6Acdc9jTsAn1/rQBWXIOc5HQioyF3nC47E1Z2kjr19aayhie9ADFRkI5+X17mkgRTKx25I9KtiPbHtC5JqWzjCJuIAbPH0oAaLFHB45IqldacUIK88cY61tKQPZjTwpIwyjPv2oA5g2RPTJoro5LbDFouAf4aKAKtxIzybiOp/Kqjq87iIHbGpG4+v0qQhsqRx3HvTohtQAcn3NACwRDc0zfeB2oP7tIsRlJ3Z8sH8zUsSiWbIyITwxq1JGEUKo4xQBQdFSNQoA2ngAVG/twKsS+nBFVmODjrj9KAIZTkEEjFUpBgkYOO1W5G9wD1HFVpeSR27c0AVGYcdj/AD/+vUUpCqMjjipZSRuDHH9fpVU/O525wvTnjNADUUk7jnJ7f3amPTgcGlQYUbs55JqN2CbuSB2PqaAEeTYpzz2FUppd5+9j0xzRJJvB55PpVc9PkI3DnHp/iaAHlie3B6Adqx9f0a31qBQ2I7pFIjl7f7re3v2rWHygkdOn4UiJkAYO3370AeJ6zp01ncy20qsksTbWUHqPamQwbdpx82AR616h410JLuzk1G3DG5t1BlTP3ox3HuP5V55IhUjaufTB60AWbS9n05lms323IYFWHb2r0Twbd3V8GuXkke2dedx4B9PrXmkERZgGIPpx1r03wKfL0ySEf6tWDBe3PWgDpgCOQAfaquqX62MQ5zIxwPTA71Mx6gnI6HNcx4mmMlwc4O35R+FAEF/qEc25r0SNCQee6eh96wDbrdYlnyzdQD1I7E1IXIZs7gc8AfrT4lIkOCcHqMUAOtrUbsRrySOg716HoliLGyWID943zyHpz2FYvhqxUbbqTLbD8gI4P/6q3ZLopIcKGQHHvn/CgDTi4BLZ5568ipWwFJYDgcYqvbyrJCrpnb2HofSid/mC9ARnp1oAytYuV3AhkV89epArHF0of53Uqx5G7v61oalsmk2J0Bz8vHHv9ayZ7CKRSREAWPGDxQAt3cxkEBuM546VattRhhs2YOcAcDHWq1rCm1shd4OD3qVwPnAXcNvIHfjqKAKen3yrqc2/eN0QI3L0waXSL6N7iYIjFVnbp6elRXMUwuo7hRuQLtbHce9W9BsxAtxcEr88hZMnpQBbubljIwijJI/2aglumC7SDnHTHJFakMarubHzH+VVhAj3JO1Tt54HSgCC0mlBRmURgN85HP5V2NhNJ8yydCc5HQj19q5zainACqOgz1rS0+4KuUmB2jG1uvFAHRhjjPcdTnGaRyNwx0P86hik3Rg565A4qu1wTIqqdo79+KAL65DdD0yKkDccfyqKN1dQwHUenQ0oOBQA9sMCT16UIA0gA7njmmFhgccn8qFPzZzjnqKALLNtYFTnJx0q3bqvlqWH3h+VZ7MF/Cp7ScsmDk4OOKALQUgnPX0qZWz161EzK4OCcD1pwJ5+WgCbA29CT6UUiPhznnAxRQBmPDhmXpj+VNjVm+ROuec9qu3anauwfN0wKI4RANvc/ePpQA1FCIFGPf3pScgr3Xv6imtjORkHoajLkFSPxoAilGck1WbgduKty4YZGc1UlHTjmgCtJjGOearuM9eT3qxJyD2J5quw5+UZXtQBXlUnDDjHBqtGo2knuTVo+nX39ag4AwB/9agBD8oLMcY6+lZ9xIZGwMbRxj+tS3MhYnaRsGfaqrHBYAjkdOn4mgBpHzE9T0/+vUeAMbhn2PenE8k53E9RQATksv5cn60AOVeckHJ/WnKMEDIznr6CgcsGwc4BxinqFA4HzHgE0AIqoQyOMq4KOPUHivMNYsDZXUtuw/1TlBkcn0NeoDPUnArk/GtsJJoZ40G5lw+O5B4I/DrQBx0fynkZHqOK6zwdLJDdrGoJjlU7wvPPb8q5dhjJ6dwK6Lwa0n9rx7MbFQlic8DFAHcXMmyMuevUelc5qoEsjE5w/I7c+lXbi9DrhTwDjiq8ce8jJxnjnqPTFAGM1q552tgeg/lWjpejvK4eXKRDuePwFbdtaJGq7skjrx0q8hGMEKMGgB0IRFVV4jUYx6D61UgdpPMYg5LkjA6jtUtywAMSnaCfmIqOCTE0gAweDkjqKAL+nSeX5iZwjNuHscdxUF1fqJCqMQQOeOn4VFPcFAFXlm9eKqOm7bzh1bhvWgBqSsrhnRgHPy8dPUVLhWw3JXkD/A1L5m6EZX7xyc+tQhsE443OAQehoApI+WnAGFDYyR/OrFtkODtB3eh7fWq0Z33Nyc/KxKhenI9aljfKgDI4GO2TQBow2ysWKKSSDuFTQQiO2RCBkknHXmq1hcfvDuzkjHXHNTrPhSS33TggnGaABmVdxJz6E9ar27gvMMjG/I7Z4plxIrNIM7VJzjpUFhJ5V3JF8uX5Xj2oA0OEjyQS45xnvTo2kDh9iKwxkE8YqKMfum+UHGcjvTd3myRRKxHmMFIx0FAGvaXTx2ZL5jYk7OeD9Kmj2sBnlj+dUbpwpRVGFX5cemKdFNs2BOuMDPNAGvbz+WxJ+YfxL7+tT+ap4Tnnp3rMEn05/Wn79vI69aAL/m49hnjBp+4OTjg9jVESh0JBOQMnHan+bt5BySegoAsEk9fyqxaSbGYMAA/86z2kPUdu49aXzDkkHBFAHQRupHC8d/arCqMH06VjWt1uQEY4FaMdxkDOcHoaALS43YPHFFJG249M8dqKAL0EXytLIPmYYH0qnMNshGa1XwPp2qhdqTz/AMBNAGfKc5GetQO3qeall5yQKryDnPrQAm8Esp6HpnvULjBGOPX2oZuo7DrmkZty5z2wTQBWlyTj0OTUDnk8j/H/AOvUkpBA6HH8qgY9zyRxk0ARuSQT368Vn3ExL+WCRjqeuamu5trlExnoR0qgQACoJPueuaAFd+Se59O9QSNwSRwen0qQsVHXn2FMKlh0x3x60AMQEtjBJ+n6YpyfKoxkZ68dfrTlAIJBOD0PpSlc8gD/ABoAVQRgZ57Z/rSEjnJyCORmhiRnAyRxj2pmcHOM9ycYoAdu5Y//AKsVUv7dLu1aF8ZIyrH+E1YZsk45Xqc+9MPJAYE/1oA4W/0yW2nZJUAYcEfwv7fWrenRtFC8cTMpf75x8wH9011lxCk8e2VVZeoz/D71QTThGcKSAOCx6n3NAEAUBVCgA4Kj+p+talpFyjMMemR1qGC0IxzgD25q6uBjbwMcD1oAnU9uWJzlf8Kc0mwZwDgHHtUSAFuefY/zplzIBwOe5xQA0EMrAknPBzUG4ibeWB255AzxSs4ERxjgdPb1zSw72ciBCxIySRkUARtIu4CT5TgHk9alnjaS1nZWJfGAQeT+FalraxxsGZVZsZ9eafdwxmNmwFZsDIFAHLzagtmhhukdAEHzfeB96rXWqpIhSEnnjLc5rauNOtZCZni3yKP4j29MVh3lpAjAQpsxxxzkdqALFk7eUpPHUYJ5q95IliGFGcZ+grMt2dvTJX1rSjfy4wCTkDnmgCKTzYnyrFtvI9x/jUsKNsj7Enoc1VnuI0Zdx4xSR3wUhTJkZyrfX+tAGlLHxwQcVmXgcyCSP5ZFHHPBH+NW2nDyY+bBJ5U5/OqM0jgYKle+RnigCOPV/kKv95j/AA8EfWtLSJXnmW7kDAIMxpjGfU/SqVs0KTKMLknOXH9fWtkCOVD5m7PtwcHv9aAJvMW6uA0RPlrnb7mrcKAghjz1Gf5UafaIEMYG4jox/wA9KnNtISWVgpOTgd6AB3xGPm29qhkmBAHJI4wTUVwHhTEo4/OqckvzcE4x27UAaCXO08HBHvV2OVZTlW46c+tYCTEycgZxj/61aFlOIsnGF9zxQBpuQinH5GmF+OT71VnuUdv3R+Udx61C055I4x04oAvpOY23L17gd607S+Vk68jrmudNx12n8/WlEpHIbDDpQB163YBB3YyPTNFcst7KVwcZHeigD1WXgcflVWQAq47HvVmQ4Bqq/U+uKAMuYEZ49iKpS4zitK7HXjrWdKSDx/8AqoAruRzmoi+1hznPHWllbp9cEiq0jncFAyT26kUAOkPPH8qo3UojXCt8x46dqknmKL82QT93NZUkhZmO75qAEdtwwck9c1EWHKnr1x6U5SFOMEY6+lRnLYC9D39KAGrliec4547VKoIHTAPoMUgTAweoOfxpSdvXqOevSgBFAUALwMcYHeo2LbSOw5p27kkjHYjNMwOTuwO+P50AN3HuM98k9aZuzkjkn171K3HYHnjHY1B1+8V544FADxITkcGkBOCT9KZnJ3ZHpjtTu44/SgBeoOBjPAzxS9A2CCM0m5VUu3yqo3McdBSW7rLEk0R3RsMqSOooAk5J684p+3AHHXgZpBx8hGfx6CpVUjJbvyTmgBrEKCxODjIIqi7lgxI5bipbh952hfkH6moQRvw2CAKAI8M8ixqCT169vWt61iEEIC5y3LH1+tZ2lQglp2U/Mfl+lai56cdfWgB2RvwMgHqPWm3bhYAc/LzjPSnEYPB9v/1UpCSoocKy9fbNAGNPMSGPQAdPr0rKFpIwJkXZngqp5+ldJexxoqqEQ55PHAFZLyQgDJ5zwFzQBWisuBsCkgd27VbjtBsG1EXPAxUYlijVdu/25zke9WYGY8bgu4dW6D0oAy72ANeQQpuVSCzEdjUYtorbUUDohidc+v61bjAOqhmfh0YA4680t+Bm2bA++RjHI49PSgCyYo/NUooVc8EcAUx4V+854PbOOaV5A0QB27j1OOgpsd0yqyOiAjoDQAz7PG75K5KnuOtaQtyduSSrDI/pVZLtFJ3blxxgd617KdJYdsbBiOw64oAm04GPcrA/iP5VI77S2Tg9etKThODx61WJ3Enjj8qAGyuGBHBz2NZ11a5VnTO3HPtV2UZA5ORxULSbVOcnd1oAyFYpIDg8cEH+L3pJLt2D5+VSOvcj/Gpr2HAVlxsPBPce9ZkuRg/KrY45oA0YLkqSGIII5P8AUVcMmVHrwVPaufLjZyB+B+77fjU8F00aKhI28Dg/doA1S53KAR+Pel8znLkAf3arK4KA7sg88UpfAG7+L35PpQBOk3UnJPfFFUnlKkf4cUUAe8yduM1Tk5OO2auS4JPPGKpTnn2/WgCrMA0ZA69vWsyfgk88itOQ8E5Ge9Zl1gE884yPagDNuH+YovXg89Bmq87LEhzyPUdTU0gCkFjkdSwrLvpjJnHRTx7UAQTyGRicjPv2FVtxIOOTnjIpZWJJ5+gqJsAZ5xjpmgBzOpyAOcY5p6AKM5468VGgJOSQfTPUU/O0dSD0oAkyFTk/hUEmMZY8gdSO1OduMHoe1Qk++T3PqKAHL8zgg5I6UZ4yAABwaaOvGPb/AAp2QFLEY4oAQ+wwOnpURBBJHH171KTlSBjj17e9RhM8HGfzoAZtLZ45AzmpFH1I+lBTngEDOck0MzDHqeM+tAFLWC0VrDcciOGZC+D1Q/Kf50ujEppwjbJa3kkhxn0P+FWZoPtNrPDjIljaP8ccfrWb4akkltpzIjHeysr9mbGGx+IoA2lYY7H9Me9QSybuMDHekmlCgqPmGMk+nrVfcwVV5zjoT+tADmYMMA98UgQyusCkZP3gOy+tKDnccsR1PGPpV21hZIg5B3yf+OigC1EFWIIoBwNuB3qymABknnvVXcF6fN/T61YRuMnIIHHP60AI3OCD+lOVht54AGTx6VE0mRxxxxg1Xuh58ZjLYVjgheM0AZet6mg3kOioFBAB5b6+lZS3sTjKSIM9MHOeaf4gdLeIOwj3OfLPy8fWsFg8LKzLuQ8HA5GOlAGsb2NpAhcgYPPp64rWhuovORmY4A7DvWPb2qcPIDzyO2K6ARAxKwUbiAQAOvsaAMya7jFxC20sAeWzgYPrT7y/hMsI5KpnIx+tLf6e12wMSqrDnnvinWmkiJGmEn7zryMkCgCKW8hLx7VnIwDwvX/61Vr/AFArchRGyDpyMke1bsSd3PXjrzWRqSLLLM5wWIGB1/GgCsL88fL+PcVq6bfu4OIXwBnO/uPSuWlDTsyo7AA4yvb61taBIUheGQkuPuk+nvQB11ldmZWSbIlUcMOAw/xoVuX3ZXHpVK1weSc4H3s9/SrC4ORzkjB56UASSttXncG9uahlfG7r/wDXpJsq2CeRyOagLYBHOB2oAc79QxyCCeOOayr2MgllI3jPPXPvVyRupAOSMjmoZDuGH7c5U9KAMYyYyxxg8A/0oST5s8HPPNOu7cxu20ZTGee/vVbOG28gNyDQBft7hlbAA3E9+Rirryr5YYDOOevSsQyeWRnJYdcf0FOF3iVScN3b1IoAspex3sCzQM3lljjeu08deDRXllreXMd7c3UEE5E7NtJJUMobqCaKAPuCXBGexFUZznjv71aH+q/A1Um/1h/3TQBSlxggZqhcjjPWrdwen+e1U5vvUAYl9LwY1P1/wrJuG5561buDmRc9yc1myHk/WgBh4brSIvPc+lNP3iOw/wAKVO34/wA6AJQAex9qazcjrjOCKSXgkDgYP86jYnLfSgBzEHnGR7VEFLN/UdKaScPyelIxIlcA8baAJ1XJ9j0PTFPU9cnBxzTB1FTuBv8AwFAEZXjIHGcc/wA6YRjIJGR71Kfvv/ug/jVZ+CuPWgB7Y5Ayfc1GPmIzj3z2ofhTj1/rTcDavHY0ASxyBACAeORiq6pDaRssSlULM+0HI3Hr+dTd1+tZt2TuibJzjrQA8vulywJyM8dqcqKJlkZQWU8N7H0qNfuH/eWpV5685BzQBYgj8yXaclRgkN39q0WYMm4AgZ5GelVLb/Vmpx0NACtkg4xnH0p0UvJBzj645qFvuk98VAxOTyfumgC/vHQ9Tz+NV2ZfMPPzD9KZGSX69qrwf6z/AIEaAOc1uR55JImY8MAD6fSmWMjS2oFwgyvy59PSmXvN5bk91fNJY8yMDyN3SgCS1m/dEDJKHGD1H0rfhmULGgbaAucA+ncVycZP2qXk9RWzbEmSHJ6KaAN5Cq5ZRycbsHvQx6Y5B4z0qpH/AKlT3p6fdT3joAWWX9yxUj72Dx0rC1O4PmyNt3DBOBwD6VsXPFu2OOQP1rm9d4WfHbbj25oAfGgECSDJLHBA6g1CL5hdqI8AOO/TcKnXhYyOuBWPfgfY4hjjzaAPQLKYNYQSkj94A3A65qyk3yg5BHtWXppP9mWozxz/ADq3BwsmOPnoAnmlH8eBjjmq0jDPrgc0pJ2nk9DVZjlBnnigAJOR2BHHNNzzhQGYcY/z701u49jTouYDn+7QBIyqyFCuV7jP8qybu3Mb7GJCHkYrUg5Bz6VW1j/j3U993WgDHlkwuDuPPaqF/O1vbSsA4bBArQP3v+A1jXhJtZ8knhhz9KAOJh1241m1kh1IokNvIPKeNSH6Hj6YxRVfVgBZWOAB8pooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Percutaneous transhepatic cholangiogram demonstrating complete transection of the common bile duct and dilation of the biliary tree. This patient was treated with a hepaticojejunostomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepaticojejunostomy for complete transection of the common bile duct after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cholangiogram of a patient with a complete transection of the common bile duct treated with hepaticojejunostomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_9_5268=[""].join("\n");
var outline_f5_9_5268=null;
var title_f5_9_5269="PMLE forearms";
var content_f5_9_5269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Polymorphous light eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photo shows a 35-year-old woman with a symmetrical papulovesicular eruption on the forearms. Lesions were also present on the neck and lower legs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Eric Ehrsam, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_9_5269=[""].join("\n");
var outline_f5_9_5269=null;
var title_f5_9_5270="Sq cell ca lung kerat";
var content_f5_9_5270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Squamous cell carcinoma with early invasive nests of keratinizing squamous epithelium.",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henry D Tazelaar MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_9_5270=[""].join("\n");
var outline_f5_9_5270=null;
var title_f5_9_5271="Propylthiouracil: Drug information";
var content_f5_9_5271=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Propylthiouracil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/31/30196?source=see_link\">",
"    see \"Propylthiouracil: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/50/15142?source=see_link\">",
"    see \"Propylthiouracil: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F10163904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Propyl-Thyracil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F215099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antithyroid Agent;",
"     </li>",
"     <li>",
"      Thioamide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F215076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hyperthyroidism:",
"     </b>",
"     Oral: Initial: 300 mg/day in 3 divided doses; 400 mg/day in patients with severe hyperthyroidism and/or very large goiters; an occasional patient will require 600-900 mg/day; usual maintenance: 100-150 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Graves&rsquo; disease (unlabeled use):",
"     </b>",
"     Oral: Initial: 50-150 mg (depending on severity) 3 times daily to restore euthyroidism; maintenance: 50 mg 2-3 times daily for a total of 12-18 months, then tapered or discontinued if TSH is normal at that time (Bahn, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Thyrotoxic crisis/thyroid storm  (unlabeled use):",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Recommendations vary widely and have not been evaluated in comparative trials. Typical dosing is 800-1200 mg/day given as 200-300 mg every 4-6 hours; some clinicians advocate an initial loading dose of 600-1000 mg. After initial response, dose may be reduced gradually to a maintenance dosage (100-600 mg/day in divided doses) (Goldberg, 2003; Nayak, 2006). The American Thyroid Association and the American Association of Clinical Endocrinologists recommend 500-1000 mg loading dose followed by 250 mg every 4 hours (Bahn, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Duration of therapy: Clinical improvement generally occurs in 1-3 months, after which dosage reduction may be employed (to prevent hypothyroidism), with discontinuation considered after 12-18 months of therapy. Thyroid function should be monitored every 2 months thereafter for 6 months until remission is confirmed, followed by annual evaluations (Cooper, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F215088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/50/15142?source=see_link\">",
"      see \"Propylthiouracil: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hyperthyroidism:",
"     </b>",
"     Oral: Children: Initial: 5-7 mg/kg/day",
"     <b>",
"      or",
"     </b>",
"     150-200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in divided doses every 8 hours",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-10 years: 50-150 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;10 years: 150-300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Administer in equally divided doses every 8 hours. Adjust dosage to maintain T",
"     <sub>",
"      3",
"     </sub>",
"     , T",
"     <sub>",
"      4",
"     </sub>",
"     , and TSH levels in normal range; elevated T",
"     <sub>",
"      3",
"     </sub>",
"     may be sole indicator of inadequate treatment. Elevated TSH indicates excessive antithyroid treatment.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F215078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adjustment is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10162707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM208533.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM208533.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9603933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer at the same time in relation to meals each day, either always with meals or always between meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F215050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy in patients intolerant of methimazole to ameliorate hyperthyroidism symptoms in preparation for surgical treatment or radioactive iodine therapy; treatment of hyperthyroidism in patients intolerant of methimazole and not candidates for surgical/radiotherapy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F10379583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of Graves' disease, thyrotoxic crisis, or thyroid storm",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F215107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Propylthiouracil may be confused with Purinethol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       PTU is an error-prone abbreviation (mistaken as mercaptopurine [Purinethol&reg;;  6-MP])",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F215097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Periarteritis, vasculitis (ANCA-positive, cutaneous, leukocytoclastic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drowsiness, drug fever, fever, headache, neuritis, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, erythema nodosum, exfoliative dermatitis, pruritus, skin pigmentation, skin rash, skin ulcers, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Goiter, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, loss of taste, nausea, sialoadenopathy, splenomegaly, stomach pain, taste perversion, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, bleeding, granulopenia, hypoprothrombinemia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Acute liver failure, cholestatic jaundice, hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure, glomerulonephritis, nephritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Alveolar hemorrhage, interstitial pneumonitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Lymphadenopathy, SLE-like syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F215054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to propylthiouracil or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F215037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Boxed warning:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: See &ldquo;Concerns related to adverse effects&rdquo; below.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: May cause hypoprothrombinemia and bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: May cause significant bone marrow depression; the most severe manifestation is agranulocytosis (commonly within first 3 months of therapy). Aplastic anemia, thrombocytopenia, and leukopenia may also occur. Use with caution in patients receiving other drugs known to cause myelosuppression particularly agranulocytosis; discontinue if significant bone marrow suppression occurs, particularly agranulocytosis or aplastic anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatitis: Has been associated with rare but severe dermatologic reactions; discontinue in the presence of exfoliative dermatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fever: Discontinue in the presence of unexplained fever.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Severe liver injury (some fatal) and acute liver failure (some cases requiring transplantation) have been reported.",
"     </b>",
"     Patients should be counseled to recognize and report symptoms suggestive of hepatic dysfunction (especially in first 6 months of treatment), which should prompt immediate discontinuation. Routine liver function test monitoring may not reduce risk due to unpredictable and rapid onset.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lupus-like syndrome: Has been associated with a variety of autoimmune reactions, including a lupus-like syndrome; discontinuation may be warranted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephritis: Has been associated with glomerulonephritis and interstitial nephritis with acute renal failure; discontinuation of therapy may be warranted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pneumonitis: Has been associated with rare reports of interstitial pneumonitis. Prompt evaluation is warranted in patients reporting respiratory signs/symptoms consistent with this reaction; discontinuation is warranted in cases or interstitial pneumonitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vasculitis: Has been associated (rarely) with the development of  ANCA-positive vasculitis or leukocytoclastic vasculitis; prompt discontinuation is warranted in patients who develop vasculitis during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Propylthiouracil should be reserved for adults or children unable to tolerate methimazole or in whom surgery or radioactive iodine treatment are not appropriate.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antithyroid Agents may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Iodide I131: Antithyroid Agents may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue antithyroid therapy 3-4 days prior to sodium iodide I-131 administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Antithyroid Agents may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antithyroid Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F215069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Propylthiouracil serum levels may be altered if taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F215043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F215058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Propylthiouracil has been found to readily cross the placenta. Teratogenic effects have not been observed; however, nonteratogenic adverse effects, including fetal and neonatal hypothyroidism, goiter, and hyperthyroidism, have been reported following maternal propylthiouracil use. The transfer of thyroid-stimulating immunoglobulins can stimulate the fetal thyroid",
"     <i>",
"      in utero",
"     </i>",
"     and transiently after delivery and may increase the risk of fetal or neonatal hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Uncontrolled maternal hyperthyroidism may result in adverse neonatal outcomes (eg, prematurity, low birth weight) and adverse maternal outcomes (eg, pre-eclampsia, congestive heart failure, stillbirth, and abortion). To prevent adverse fetal and maternal events, normal maternal thyroid function should be maintained prior to conception and throughout pregnancy. Antithyroid treatment is recommended for the control of hyperthyroidism during pregnancy. Propylthiouracil is considered first-line therapy, especially during the first trimester. Due to an increased risk of liver toxicity, use of methimazole may be preferred during the second and third trimesters. If drug therapy is changed, maternal thyroid function should be monitored after 2 weeks and then every 2-4 weeks. Propylthiouracil, along with other medications, is used for the treatment of thyroid storm in pregnant women; alternative therapy is recommended if oral administration is not possible.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The pharmacokinetics of propylthiouracil are not significantly changed during pregnancy; however, the severity of hyperthyroidism may fluctuate throughout pregnancy. Doses of propylthiouracil may be decreased as pregnancy progresses and discontinued weeks to months prior to delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F215081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/AAP rates &ldquo;compatible&rdquo; (AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5270920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Propylthiouracil is excreted in human breast milk; however, the infant dose is considered low and unlikely to affect infant thyroid hormones. The American Thyroid Association considers doses &lt;300 mg/day to be safe during breast-feeding (Stagnaro-Green, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F215059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take at the same time in relation to meals each day, either always with meals or always between meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F215057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Propylthiouracil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $74.64",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F215045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, prothrombin time, liver function tests (bilirubin, alkaline phosphatase, transaminases), and thyroid function tests (TSH, T",
"     <sub>",
"      3",
"     </sub>",
"     , T",
"     <sub>",
"      4",
"     </sub>",
"     ) every 4-6 weeks until euthyroid; periodic blood counts are recommended for chronic therapy",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F215048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Normal laboratory values:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Total T",
"     <sub>",
"      4",
"     </sub>",
"     : 5-12 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum T",
"     <sub>",
"      3",
"     </sub>",
"     : 90-185 ng/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Free thyroxine index (FT",
"     <sub>",
"      4",
"     </sub>",
"     I): 6-10.5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     TSH: 0.5-4.0 microunits/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Antiroid (KP);",
"     </li>",
"     <li>",
"      Bingsaiyou (CL);",
"     </li>",
"     <li>",
"      Peteyu (TH);",
"     </li>",
"     <li>",
"      Procarbizol (PK);",
"     </li>",
"     <li>",
"      Procil (TW);",
"     </li>",
"     <li>",
"      Propycil (BG, CH, CZ, DE, HN, HU, PT, TR);",
"     </li>",
"     <li>",
"      Propyl (TH);",
"     </li>",
"     <li>",
"      Propyl-Thiouracil (CH);",
"     </li>",
"     <li>",
"      Propylthiocil (IL);",
"     </li>",
"     <li>",
"      Propylthiouracil &rdquo;Dak&rdquo; (DK);",
"     </li>",
"     <li>",
"      Propylthiouracile (BE);",
"     </li>",
"     <li>",
"      Propyltiouracil &rdquo;Medic&rdquo; (DK);",
"     </li>",
"     <li>",
"      Proracyl (FR);",
"     </li>",
"     <li>",
"      Prothiucil (AT);",
"     </li>",
"     <li>",
"      Prothuril (GR);",
"     </li>",
"     <li>",
"      PTU (AU, IN, UY);",
"     </li>",
"     <li>",
"      Thyrosan (PL);",
"     </li>",
"     <li>",
"      Tiotil (EE, SE);",
"     </li>",
"     <li>",
"      Tirostat (CO, EC);",
"     </li>",
"     <li>",
"      Uracil (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F215036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits the synthesis of thyroid hormones by blocking the oxidation of iodine in the thyroid gland; blocks synthesis of thyroxine and triiodothyronine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F215053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Concentrated in the thyroid gland",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 80% to 85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 53% to 88%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (35%; primarily as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aloush V, Litinsky I, Caspi D, et al, &ldquo;Propylthiouracil-Induced Autoimmune Syndromes: Two Distinct Clinical Presentations With Different Course and Management,&rdquo;",
"      <i>",
"       Semin Arthritis Rheum",
"      </i>",
"      , 2006, 36(1):4-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/16887463/pubmed\" id=\"16887463\" target=\"_blank\">",
"        16887463",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/11533352 /pubmed\" id=\"11533352 \" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, ACOG Practice Bulletin, Clinical Management Guidelines for Obstetrician-Gynecologists, Number 37, August 2002. (Replaces Practice Bulletin Number 32, November 2001), &ldquo;Thyroid Disease in Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2002, 100(2):387-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/12166417/pubmed\" id=\"12166417\" target=\"_blank\">",
"        12166417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bahn RS (Chair), Burch HB, Cooper DS, et al, &ldquo;Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists,&rdquo;",
"      <i>",
"       Thyroid",
"      </i>",
"      , 2011, 21(6):593-646.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/ 21510801/pubmed\" id=\" 21510801\" target=\"_blank\">",
"        21510801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Casis FC and Perez JB, &ldquo;Leukocytoclastic Vasculitis: A Rare Manifestation of Propylthiouracil Allergy,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2000, 6(4):329-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/11242611/pubmed\" id=\"11242611\" target=\"_blank\">",
"        11242611",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clark SM, Saade GR, Snodgrass WR, et al, &ldquo;Pharmacokinetics and Pharmacotherapy of Thionamides in Pregnancy,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 2006, 28(4):477-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/16885714/pubmed\" id=\"16885714\" target=\"_blank\">",
"        16885714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Groot L, Abalovich M, Alexander EK, et al, &ldquo;Management of Thyroid Dysfunction During Pregnancy and Postpartum: An Endocrine Society Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2012, 97(8):2543-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/22869843/pubmed\" id=\"22869843\" target=\"_blank\">",
"        22869843",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper DS, \"Antithyroid Drugs,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(9):905-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/15745981/pubmed\" id=\"15745981\" target=\"_blank\">",
"        15745981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diav-Citrin O and Ornoy A, &ldquo;Teratogen Update: Antithyroid Drugs &minus; Methimazole, Carbimazole, and Propylthiouracil,&rdquo;",
"      <i>",
"       Teratology",
"      </i>",
"      , 2002, 65(1):38-44",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/11835230/pubmed\" id=\"11835230\" target=\"_blank\">",
"        11835230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erten Y, Bodur H, Sahiner S, et al, &ldquo;Antineutrophil Cytoplasmic Antibody Associated Vasculitis and Rapidly Progressive Glomerulonephritis as a Complication of Propylthiouracil Therapy,&rdquo;",
"      <i>",
"       Clin Endocrinol (Oxf)",
"      </i>",
"      , 2002, 57(5):699-700.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/12390348/pubmed\" id=\"12390348\" target=\"_blank\">",
"        12390348",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldberg PA and Inzucchi SE, \"Critical Issues in Endocrinology,\"",
"      <i>",
"       Clin Chest Med",
"      </i>",
"      , 2003, 24(4):583-606.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/14710692/pubmed\" id=\"14710692\" target=\"_blank\">",
"        14710692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ichiki Y, Akahoshi M, Yamashita N, et al, &ldquo;Propylthiouracil-Induced Severe Hepatitis: A Case Report and Review of the Literature,&rdquo;",
"      <i>",
"       J Gastroenterol",
"      </i>",
"      , 1998, 33(5):747-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/9773944/pubmed\" id=\"9773944\" target=\"_blank\">",
"        9773944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson DG and Campbell S, &ldquo;Hormonal and Metabolic Agents,&rdquo;",
"      <i>",
"       Geriatric Pharmacology",
"      </i>",
"      , Bressler R and Katz MD, eds, New York, NY: McGraw-Hill, 1993, 427-50.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren G and Soldin O, &ldquo;Therapeutic Drug Monitoring of Antithyroid Drugs in Pregnancy: The Knowledge Gaps,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 2006, 28(1):12-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/16418686/pubmed\" id=\"16418686\" target=\"_blank\">",
"        16418686",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee A, Moretti, ME, Collantes A, et al, &ldquo;Choice of Breastfeeding and Physicians' Advice: A Cohort Study of Women Receiving Propylthiouracil,",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 106(1 Pt 1):27-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/10878145/pubmed\" id=\"10878145\" target=\"_blank\">",
"        10878145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liaw YF, Huang MJ, Fan KD, et al, &ldquo;Hepatic Injury During Propylthiouracil Therapy in Patients With Hyperthyroidism. A Cohort Study,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1993, 118(6):424-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/8439116/pubmed\" id=\"8439116\" target=\"_blank\">",
"        8439116",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Limaye A and Ruffolo R, &ldquo;Propylthiouracil-Induced Fatal Hepatic Necrosis,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 1987, 82(2):152-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/3812421/pubmed\" id=\"3812421\" target=\"_blank\">",
"        3812421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lock DR and Sthoeger ZM, &ldquo;Severe Hepatotoxicity on Beginning Propylthiouracil Therapy,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 1997, 24(4):267-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/9252857/pubmed\" id=\"9252857\" target=\"_blank\">",
"        9252857",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mandel SJ and Cooper DS, &ldquo;The Use of Antithyroid Drugs in Pregnancy and Lactation,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2001, 86(6):2354-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/11397822/pubmed\" id=\"11397822\" target=\"_blank\">",
"        11397822",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mihas AA, Holley P, Koff RS, et al, &ldquo;Fulminant Hepatitis and Lymphocyte Sensitization Due to Propylthiouracil,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1976, 70(5 PT.1):770-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/1261772/pubmed\" id=\"1261772\" target=\"_blank\">",
"        1261772",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nayak B and Burman K, &ldquo;Thyrotoxicosis and Thyroid Storm,&rdquo;",
"      <i>",
"       Endocrinol Metab Clin North Am",
"      </i>",
"      , 2006, 35(4):663-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/17127140/pubmed\" id=\"17127140\" target=\"_blank\">",
"        17127140",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nguyen LT, Luong KV, and Pham BV, &ldquo;An Antineutrophil Cytoplasmic Autoantibody Associated With a Propylthiouracil-Induced Adult Respiratory Distress-Like Syndrome: Report of a Case and Review of the Literature,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 1998, 4(2):89-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/15251752/pubmed\" id=\"15251752\" target=\"_blank\">",
"        15251752",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Park KE, Chipps DR, and Benson EM, &ldquo;Necrotizing Vasculitis Secondary to Propylthiouracil Presenting as Purpura Fulminans,&rdquo;",
"      <i>",
"       Rheumatology (Oxford)",
"      </i>",
"      , 1999, 38(8):790-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/10501437/pubmed\" id=\"10501437\" target=\"_blank\">",
"        10501437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raby C, Lagorce JF, Jambut-Absil AC, et al, &ldquo;The Mechanism of Action of Synthetic Antithyroid Drugs: Iodine Complexation During Oxidation of Iodide,&rdquo;",
"      <i>",
"       Endocrinology",
"      </i>",
"      , 1990, 126(3):1683-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/1689656/pubmed\" id=\"1689656\" target=\"_blank\">",
"        1689656",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Romas E, Henderson DR, and Kirkham BW, &ldquo;Propylthiouracil Therapy: An Unusual Cause of Antineutrophil Cytoplasmic Antibody Associated Alveolar Hemorrhage,&rdquo;",
"      <i>",
"       J Rheumatol",
"      </i>",
"      , 1995, 22(4):803.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/7791200/pubmed\" id=\"7791200\" target=\"_blank\">",
"        7791200",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ruiz JK, Rossi GV, Vallejos HA, et al, &ldquo;Fulminant Hepatic Failure Associated With Propylthiouracil,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2003, 37(2):224-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/12549953/pubmed\" id=\"12549953\" target=\"_blank\">",
"        12549953",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sheen YS, Chu CY, and Yu HS, &ldquo;Antineutrophil Cytoplasmic Antibody-Positive Cutaneous Leukocytoclastic Vasculitis Associated With Propylthiouracil Therapy,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 2006, 142(7):879-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/16847204/pubmed\" id=\"16847204\" target=\"_blank\">",
"        16847204",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stagnaro-Green A, Abalovich M, Alexander E, et al, \"Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum,\"",
"      <i>",
"       Thyroid",
"      </i>",
"      , 2011, 21(10):1081-125.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/21787128/pubmed\" id=\"21787128\" target=\"_blank\">",
"        21787128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stankus SJ and Johnson NT, &ldquo;Propylthiouracil-Induced Hypersensitivity Vasculitis Presenting as Respiratory Failure,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 1992, 102(5):1595-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/1424898/pubmed\" id=\"1424898\" target=\"_blank\">",
"        1424898",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Westphal SA, &ldquo;Hepatotoxicity From Propylthiouracil,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1994, 87(9):943-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/8091264/pubmed\" id=\"8091264\" target=\"_blank\">",
"        8091264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yu F, Chen M, Gao Y, et al, &ldquo;Clinical and Pathological Features of Renal Involvement in Propylthiouracil-Associated ANCA-Positive Vasculitis,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2007, 49(5):607-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/9/5271/abstract-text/17472842/pubmed\" id=\"17472842\" target=\"_blank\">",
"        17472842",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9830 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_9_5271=[""].join("\n");
var outline_f5_9_5271=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10163904\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215073\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215099\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215076\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215088\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215078\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215047\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215033\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10162707\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9603933\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215050\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379583\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215107\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215097\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215054\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215037\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299953\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215042\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215069\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215043\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215058\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215081\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5270920\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215059\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215057\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215045\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215048\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038787\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215036\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215053\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9830\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9830|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/31/30196?source=related_link\">",
"      Propylthiouracil: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/50/15142?source=related_link\">",
"      Propylthiouracil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_9_5272="Pathogenesis and etiology of syncope";
var content_f5_9_5272=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis and etiology of syncope",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/9/5272/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/9/5272/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/9/5272/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/9/5272/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/9/5272/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/9/5272/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/9/5272/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope is the abrupt and transient loss of consciousness associated with absence of postural tone, followed by complete and usually rapid spontaneous recovery. This symptom is alarming for the individual, witnesses, family, and physicians. Although syncope can be a harbinger of a multitude of disease processes and can mimic the appearance of a cardiac arrest, it is most often benign and self-limited. Nevertheless, injuries associated with syncopal attacks occur in about one-third of patients, and recurrent episodes can be psychologically devastating. In addition, syncope can be a premonitory sign of cardiac arrest, especially in patients with organic heart disease.",
"   </p>",
"   <p>",
"    The cause of syncope is often not obvious, and individuals at highest risk for sudden death can be difficult to detect (",
"    <a class=\"graphic graphic_table graphicRef64301 \" href=\"UTD.htm?8/31/8701\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/1\">",
"     1",
"    </a>",
"    ]. It is important to recognize that syncope and cardiac arrest are two different entities that must be distinguished from each other in order to accurately assess future outcome and prognosis. Patients in whom cardiopulmonary resuscitation, or electric or pharmacologic cardioversion have been required should be labeled as having cardiac arrest and not as having syncope. These two diagnostic entities are inextricably intertwined, however, since patients with cardiac syncope have a high incidence of subsequent cardiac arrest (approximately 24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, and etiology of syncope will be reviewed here. The evaluation and management of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28855?source=see_link\">",
"     \"Management of the patient with syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis and etiology of syncope are the same as that for presyncope, which is the prodromal symptom of fainting. Such patients usually present with symptoms of dizziness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23223?source=see_link\">",
"     \"Approach to the patient with dizziness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope is a common clinical problem [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/3\">",
"     3",
"    </a>",
"    ]. In one of the largest epidemiologic studies that evaluated the incidence and prognosis of syncope, 822 of 7814 men and women (11 percent) who were followed for an average of 17 years as part of the Framingham Heart Study reported a syncopal episode [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/4\">",
"     4",
"    </a>",
"    ]. The incidence of syncope increased with age, with a sharp rise at age 70 years (",
"    <a class=\"graphic graphic_figure graphicRef82449 \" href=\"UTD.htm?38/1/38941\">",
"     figure 1",
"    </a>",
"    ). The increased risk of syncope in elderly patients appears to be due to age- and disease-related abnormalities that impair the ability to respond to physiologic stresses that would ordinarily not cause syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of syncope was similar among men and women in the Framingham study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/4\">",
"     4",
"    </a>",
"    ], although others have reported a slight female predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/2\">",
"     2",
"    </a>",
"    ]. Men are more likely than women to have a cardiac cause of syncope (",
"    <a class=\"graphic graphic_figure graphicRef77511 \" href=\"UTD.htm?31/45/32477\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variation in the reported incidence of syncope in different studies is due to varying study populations, definitions of syncope, and diagnostic methods and criteria. Nevertheless, approximately one-third of individuals are likely to have a syncopal episode during their lifetime [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ]. In over 75 percent of cases in nonelderly subjects, syncope occurs as an isolated event (ie, not due to known neurologic or cardiovascular disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Syncope is also a common clinical complaint of patients treated in the emergency department and is the source for a significant number of hospital admissions. Several reports found that 3 to 5 percent of all emergency department admissions and 1 percent of all hospital admissions were for syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/2,8-10\">",
"     2,8-10",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease is a major risk factor for syncope. The age-adjusted incidence rate among participants with cardiovascular disease was almost twice that of participants without cardiovascular disease in the Framingham cohort (10.6 versus 6.4 per 1000 person-years) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/4\">",
"     4",
"    </a>",
"    ]. Other risk factors include a history of stroke or transient ischemic attack (odds ratio 2.56) and hypertension (odds ratio 1.46) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/11\">",
"     11",
"    </a>",
"    ]. Additional factors that have been marginally associated with the prediction of syncope include lower body mass index, increased alcohol intake, and diabetes or elevated blood glucose concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CAUSES OF SYNCOPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining the cause of syncope is important for both prognostic and therapeutic reasons. Several large studies have assessed the causes for syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/4,12-15\">",
"     4,12-15",
"    </a>",
"    ]. In general, vasovagal attacks are the most common cause of syncope, followed by cardiac etiologies. The cause is unknown in approximately one-third of cases (",
"    <a class=\"graphic graphic_table graphicRef55289 \" href=\"UTD.htm?40/15/41211\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68080 \" href=\"UTD.htm?31/38/32363\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Organization of the causes of syncope into categories aids evaluation and treatment and accurate assessment of prognosis. (",
"    <a class=\"graphic graphic_table graphicRef64301 \" href=\"UTD.htm?8/31/8701\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiac causes of syncope include structural heart disease leading to abrupt episodic drops in cardiac output by various mechanisms, poorly tolerated supraventricular and ventricular tachycardias and bradycardias. Patients with an underlying cardiovascular cause of syncope have higher rates of sudden cardiac death (SCD) and all-cause mortality than those with a noncardiovascular cause of syncope. The mortality rate in patients with cardiovascular disease after five years of follow-up has been reported to approach 50 percent, with a 30 percent incidence of death in the first year (",
"    <a class=\"graphic graphic_figure graphicRef53302 \" href=\"UTD.htm?23/2/23598\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/2,4,9,10\">",
"     2,4,9,10",
"    </a>",
"    ]. Mortality in these patients is in large part due to the severity of the underlying CVD. The presence of cardiovascular disease, however, does not necessarily indicate that syncope was caused by a cardiovascular condition.",
"   </p>",
"   <p>",
"    Cerebrovascular disease with vertebrobasilar steal is an uncommon cause of syncope and is a diagnosis of exclusion.",
"   </p>",
"   <p>",
"    Syncope due to neither cardiac nor cerebrovascular abnormalities is generally associated with a relatively benign prognosis. The most prominent causes include neurally-mediated (reflex) syncope (includes neurocardiogenic or vasovagal syncope, carotid sinus hypersensitivity, and situational syncope), and orthostatic hypotension (",
"    <a class=\"graphic graphic_table graphicRef64301 \" href=\"UTD.htm?8/31/8701\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cardiac arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias (bradycardias and tachycardias) are the most common cardiac causes of syncope. A pooled analysis of five population-based studies including 1002 patients with syncope between 1984 and 1990 found that arrhythmias were responsible for 14 percent of syncope cases (range 4 to 38 percent in different studies) (",
"    <a class=\"graphic graphic_table graphicRef55289 \" href=\"UTD.htm?40/15/41211\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/14\">",
"     14",
"    </a>",
"    ]. Arrhythmias may also be the etiology of a significant proportion of syncopal events that are unexplained after an initial evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although an arrhythmic etiology for syncope is often suspected clinically, the culprit arrhythmia frequently cannot be diagnosed since most are paroxysmal and infrequent. An additional factor that confounds accurate diagnosis is that rhythm disturbances in general are common, even among patients in whom syncope has not occurred. As a result, the presence of an arrhythmia (such as",
"    <strong>",
"     asymptomatic",
"    </strong>",
"    sinus bradycardia or nonsustained ventricular tachycardia [VT] on an ambulatory monitor recording) does not necessarily mean that the arrhythmia is the cause for syncope. Furthermore, if the true etiology of syncope results in a secondary arrhythmia, treatment of the rhythm disturbance will not prevent recurrent syncope. As an example, a \"relative\" bradycardia is often seen during a vasovagal episode and although it is associated with syncope, treatment of the bradycardia rarely prevents recurrent symptoms.",
"   </p>",
"   <p>",
"    In contrast to patients who have vasovagal or other causes of syncope, an arrhythmic cause of syncope often occurs without warning. This is particularly true of the bradyarrhythmias and, in addition to reporting no warning symptoms, the patient may also suffer an injury with the event. Patients with a tachyarrhythmia may report having palpitations.",
"   </p>",
"   <p>",
"    Tachycardias are usually more hemodynamically unstable and are less well tolerated than bradycardias, especially at the onset of the arrhythmia. Both forms of rhythm disturbances are more likely to cause a syncopal response if the rhythm begins abruptly. This is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic sinus bradycardia is often well tolerated, while sinus rhythm with abrupt sinus arrest and a long sinus pause frequently causes symptoms.",
"     </li>",
"     <li>",
"      Persistent atrial flutter with a ventricular response rate of 150 beats per minute will often be asymptomatic, while paroxysmal VT at the same rate may cause syncope.",
"     </li>",
"     <li>",
"      The initiation of a tachycardia is frequently associated with hypotension and syncope; however, if the rhythm persists, the blood pressure can rise and the patient becomes asymptomatic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The hemodynamic stability resulting from any arrhythmia is also influenced by other factors including rate, ventricular function, body position, medications, and baroreceptor sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VT and bradyarrhythmias secondary to ischemia were considered to be the cause for syncope in only 1 percent of cases described in early series of syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/21\">",
"     21",
"    </a>",
"    ]. These data are similar to others in the literature. As a result, although patients who are admitted to the hospital with syncope are commonly tested for a recent myocardial infarction (MI), this procedure is rarely (if ever) necessary since syncope is infrequently caused by MI.",
"   </p>",
"   <p>",
"    The more common arrhythmic causes of syncope include sinus bradycardia, atrioventricular (AV) nodal block (in which episodes of presyncope or syncope are called Stokes-Adams attacks), sustained VT, and supraventricular tachycardia (SVT).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinus bradycardia &mdash; Syncope resulting from sinus bradycardia may be caused by intrinsic sinus node disease (sick sinus syndrome, tachy-brady syndrome), drugs (beta blockers, including ophthalmologic application), or autonomic imbalance (high vagal or decreased sympathetic tone). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3878?source=see_link\">",
"       \"Sinus bradycardia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Conduction abnormalities &mdash; The forms of AV block that can result in syncope are usually second or third degree AV block.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, type I (Wenckebach) second degree AV block is benign and not progressive. If the QRS is narrow, the majority of cases are due to block at the level of the AV node. Type II second degree AV block is associated with significant conduction disease, such as a bundle branch block, and the site of block is usually infranodal. Type II block is often progressive, is more commonly associated with syncope.",
"   </p>",
"   <p>",
"    When type I or type II second degree AV block or third degree AV block is present in conjunction with syncope a permanent pacemaker is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type II\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=see_link\">",
"     \"Third degree (complete) atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with syncope who have an underlying bundle branch block, syncope may be due to prolonged asystolic pauses caused by paroxysmal AV block, even if an electrophysiologic test fails to document any definite abnormalities in the AV node or His-Purkinje system [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/22\">",
"     22",
"    </a>",
"    ]. However, syncope patients with bundle branch block are also at risk for ventricular tachycardia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventricular tachycardia &mdash; Syncope resulting from VT is most commonly due to structural heart disease, particularly coronary heart disease. In these patients, other factors, such as baroreceptor sensitivity, may be important in determining hemodynamic tolerability of VT. As an example, one study of 24 patients with sustained monomorphic VT after an MI reported that patients with syncope or presyncope who had lower baroreceptor sensitivity (as assessed with an infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"       phenylephrine",
"      </a>",
"      ) tolerated VT significantly less well than those with normal baroreceptor responses [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with dilated cardiomyopathy and right ventricular dysplasia are also prone to have VT presenting with syncope. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    .) In addition, an unusual form of VT, torsades de pointes, may cause syncope in patients with either the congenital or acquired forms of the long QT syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"     \"Clinical features of congenital long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ventricular fibrillation does not cause syncope. Instead, this rhythm disturbance causes cardiac arrest and death.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventricular bigeminy &mdash; Ventricular bigeminy may occasionally be associated with hypotension, bradycardia, and syncope. This is seen primarily in patients with an underlying sinus bradycardia or those with advanced heart disease and significant left ventricular dysfunction.",
"     </li>",
"     <li>",
"      Supraventricular tachyarrhythmias &mdash; Supraventricular tachyarrhythmias have rarely been associated with syncope [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/23\">",
"       23",
"      </a>",
"      ]. Syncope occurring at the onset of the arrhythmia correlates with the rate, while impaired vasomotor function may be responsible for syncope during an episode, suggesting a role for neurally mediated (neurocardiogenic) responses rather than a direct result of the tachycardia [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/24-26\">",
"       24-26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Organized and regular SVTs cause syncope more frequently than disorganized supraventricular rhythm disturbances. Such regular SVTs include AV nodal reentry or AV reentry tachycardia (with antegrade conduction over the AV node and retrograde conduction over an accessory pathway), or the atrial fibrillation with Wolff-Parkinson-White Syndrome (in which AV conduction proceeds via the AV node and an accessory pathway). By comparison, atrial fibrillation, without very rapid AV conduction rarely causes syncope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Structural cardiac or cardiopulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structural cardiac or cardiopulmonary disease that may lead to syncope due to inadequate cardiac output include cardiac valvular disease (particularly aortic stenosis), hypertrophic cardiomyopathy, atrial myxoma, pulmonary embolus, pulmonary hypertension, pericardial tamponade, acute myocardial",
"    <span class=\"nowrap\">",
"     infarction/ischemia,",
"    </span>",
"    and acute aortic dissection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Blood flow obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope may be caused by obstruction to blood flow due to cardiovascular abnormalities, the most frequent being aortic stenosis and hypertrophic cardiomyopathy. Less common conditions include pulmonic stenosis, idiopathic pulmonary arterial hypertension, atrial myxomas, and pulmonary embolism.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aortic stenosis &mdash; Aortic stenosis rarely presents with syncope unless the valve is critically stenotic. Recognition of this association is exceedingly important since it is associated with a high mortality if untreated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30551?source=see_link\">",
"       \"Natural history of aortic stenosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Syncope in patients with aortic stenosis is often associated with exertion. In most such cases, syncope results from an inability to produce a compensatory increase in cardiac output (due to the obstruction) which normally occurs in response to exercise-induced peripheral vasodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/27\">",
"     27",
"    </a>",
"    ]. In others, the most probable cause of syncope is an exaggerated, more malignant form of a vasovagal response. This may have the same mechanism as vasovagal syncope, which is due to the stimulation of ventricular mechanoreceptors. A bradyarrhythmia or ventricular tachyarrhythmia may also be a cause for syncope in some of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertrophic cardiomyopathy &mdash; Syncope may occur in up to 30 percent of patients who have dynamic outflow obstruction due to hypertrophic cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/29\">",
"       29",
"      </a>",
"      ]. The obstruction can intensify with postural changes, hypovolemia, or drugs. VT has also been reported to occur in approximately 25 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other causes of outflow obstruction &mdash; Severe pulmonic stenosis, idiopathic pulmonary arterial hypertension, atrial myxomas, and pulmonary embolism can all cause syncope due to obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neurally-mediated syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Types of reflex syncope including vasovagal (neurocardiogenic) syncope, situational syncope and carotid sinus hypersensitivity are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10598?source=see_link\">",
"     \"Carotid sinus hypersensitivity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vasovagal syncope (also known as neurocardiogenic or vasodepressor syncope) is a common cause of syncope, particularly in patients without apparent cardiac or neurologic disease. In contrast to vasovagal syncope, carotid sinus hypersensitivity is much more common in older than younger patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Orthostatic hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthostatic hypotension is defined as a postural decrease in systolic blood pressure of at least 20 mmHg, in diastolic blood pressure of at least 10 mmHg, or symptoms. Orthostatic hypotension accounted for 8.6 and 9.9 percent of syncope cases among men and women in the Framingham cohort, respectively, and for 8 percent of cases in the five pooled cohort studies (",
"    <a class=\"graphic graphic_table graphicRef55289 \" href=\"UTD.htm?40/15/41211\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68080 \" href=\"UTD.htm?31/38/32363\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/4,14\">",
"     4,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major causes of orthostatic hypotension associated with syncope include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreased intravascular volume, as may occur with diuretics",
"     </li>",
"     <li>",
"      Drug effects, especially antidepressants (tricyclics, phenothiazine) and antihypertensive agents (beta and alpha blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      , ACE inhibitors, ganglionic blockers), particularly vasodilators, including calcium channel blockers and nitrates (more commonly observed in older adults). Other drugs that may cause orthostatic hypotension include opiates and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Primary autonomic insufficiency or failure (including Shy-Drager syndrome, Parkinson disease, and others)",
"     </li>",
"     <li>",
"      Secondary autonomic insufficiency (eg, diabetes mellitus and amyloidosis)",
"     </li>",
"     <li>",
"      Alcohol consumption which impairs vasoconstriction [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Aging is associated with an increased prevalence of orthostatic hypotension [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/32\">",
"       32",
"      </a>",
"      ]. One contributory mechanism is attenuation of the vestibulosympathetic reflex [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=see_link\">",
"     \"Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cerebrovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atherosclerotic disease of the cerebral arteries had previously been considered a common cause for syncope. However, it rarely causes true syncopal symptoms. Instead, stroke and transient ischemia attacks cause focal neurologic deficits that do not recover rapidly or completely. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the posterior cerebral circulation is impaired (vertebrobasilar artery insufficiency), symptoms such as dizziness are more apt to occur than syncope.",
"     </li>",
"     <li>",
"      If the anterior circulation is compromised, a focal neurologic deficit and not a global decrease in consciousness will occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rare exception in which syncope can occur is with severe obstructive four vessel cerebrovascular disease; however, other neurologic findings are likely to occur PRIOR to the loss of consciousness in these patients.",
"   </p>",
"   <p>",
"    A vascular steal syndrome occurs when the arterial circulation to the arm is blocked resulting in a shunt of blood through the cerebrovascular system which supplies both part of the brain and the arm [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/1\">",
"     1",
"    </a>",
"    ]. Impairment in brain perfusion during arm exercise may cause loss of consciousness. Vertebrobasilar steal is associated with vertigo, diplopia, blurred vision, cranial nerve dysfunction, drop attacks (sudden fall without loss of consciousness), as well as syncope. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36471?source=see_link&amp;anchor=H5#H5\">",
"     \"Subclavian steal syndrome\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36471?source=see_link&amp;anchor=H6#H6\">",
"     \"Subclavian steal syndrome\", section on 'Symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SYNCOPE OF UNKNOWN ORIGIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in whom an etiology for the symptoms of syncope is not found after an initial evaluation are categorized as having syncope of unknown origin. This definition, however, is strongly dependent upon the modalities used for diagnosis. Thus, a patient with an unknown etiology in one study may be recognized as having a clear diagnosis in another based upon different diagnostic methods and analysis. As an example, a patient in whom electrophysiologic testing is performed for the analysis of syncope may be considered to have syncope of unknown origin if the study is negative, even though an arrhythmic cause for syncope was suspected. The prognosis would be considered to be excellent in this setting if other diagnostic studies were also negative. The same patient, however, might have a significantly different diagnosis and a poorer prognosis if one or more episodes of asymptomatic nonsustained VT were noted on an ambulatory monitor.",
"   </p>",
"   <p>",
"    Such differences in the degree of evaluation complicate the interpretation of different reports in the literature. Nevertheless, in both the Framingham cohort and the pooled analysis of five cohort studies syncope of unknown origin accounted for approximately one-third of cases (",
"    <a class=\"graphic graphic_table graphicRef55289 \" href=\"UTD.htm?40/15/41211\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68080 \" href=\"UTD.htm?31/38/32363\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/4,14\">",
"     4,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the group of patients diagnosed with syncope of unknown cause is generally heterogeneous, some cases have a benign cause, while others may have an undiagnosed cardiac cause. Thus the risk associated with this group overall is intermediate with an approximately 5 percent one year mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CAUSES OF NONSYNCOPAL ATTACKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episodes that may be confused with syncope include disorders without impairment of consciousness and disorders with partial or complete loss of consciousness (",
"    <a class=\"graphic graphic_table graphicRef76023 \" href=\"UTD.htm?23/58/24491\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures are the probable cause in 5 to 15 percent of apparent syncopal episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5272/abstract/4,14,21,34\">",
"     4,14,21,34",
"    </a>",
"    ]. They can mimic syncope, especially when the seizure is atypical and not associated with tonic-clonic movements, the seizure is not observed, or a complete history cannot be obtained.",
"   </p>",
"   <p>",
"    Another potentially confounding factor is that loss of cerebral blood flow due to any cause of syncope can result in a seizure-like state. As an example, the initiation of a rapid VT may be associated with impaired cerebral blood flow, followed within seconds by tonic-clonic movements. This apparent seizure activity is associated with brain wave slowing, not epileptiform spikes, on the EEG.",
"   </p>",
"   <p>",
"    One distinguishing feature is that patients with seizures rarely have an abrupt and complete recovery. Instead, the postictal state is characterized by a slow and complete recovery. Another important clue, if present, is evidence of soft tissue injury at multiple sites due to tonic-clonic movements during the seizure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link&amp;anchor=H17#H17\">",
"     \"Evaluation of syncope in adults\", section on 'Distinction of syncope from seizures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Metabolic or toxic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic or toxic abnormalities are rarely associated with an abrupt onset or complete brisk recovery; syncope is therefore rare in this setting. Hypoglycemia and encephalitis can cause coma, stupor, and confusion, but rarely syncope. Nevertheless, if a patient does not recall the history surrounding the event or if the event was unwitnessed, distinguishing coma from syncope can be difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis is an acute, potentially lethal, multisystem syndrome resulting from the sudden release of mast cell- and basophil-derived mediators into the circulation. Anaphylaxis typically presents with a combination of cutaneous, respiratory, and cardiovascular symptoms (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"UTD.htm?20/36/21068\">",
"     table 5",
"    </a>",
"    ). However, it may also present as an isolated sudden decrease in blood pressure, leading to presyncope or collapse, without accompanying respiratory or cutaneous symptoms. This dramatic presentation is seen most often in severe anaphylaxis triggered by insect venom and intravenous medications, although it may occur in episodes triggered by other allergens as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38888?source=see_link\">",
"     \"Differential diagnosis of anaphylaxis in children and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     INFORMATION FOR PATIENTS",
"    </strong>",
"    &mdash; UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/5/36946?source=see_link\">",
"       \"Patient information: Syncope (fainting) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/9/4245?source=see_link\">",
"       \"Patient information: Syncope (fainting) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cause of syncope is often not obvious, and individuals at highest risk for sudden death can be difficult to detect (",
"      <a class=\"graphic graphic_table graphicRef64301 \" href=\"UTD.htm?8/31/8701\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cardiac causes of syncope include structural heart disease and arrhythmias. Patients with an underlying cardiovascular cause of syncope have higher rates of sudden cardiac death and all-cause mortality than those with a noncardiovascular cause of syncope. Mortality in these patients is in large part due to the severity of the underlying cardiovascular disease. The presence of cardiovascular disease, however, does not necessarily indicate that syncope was caused by a cardiovascular condition.",
"     </li>",
"     <li>",
"      Cerebrovascular disease with vertebrobasilar steal is an uncommon cause of syncope.",
"     </li>",
"     <li>",
"      When cardiac or cerebrovascular abnormalities are not diagnosed, syncope is generally associated with a relatively benign prognosis. The most prominent causes include neurally-mediated (reflex) syncope (includes neurocardiogenic or vasovagal syncope, situational syncope, and carotid sinus hypersensitivity), and orthostatic hypotension.",
"     </li>",
"     <li>",
"      Since the group of patients diagnosed with syncope of unknown cause is generally heterogeneous, some cases have a benign cause, while others may have an undiagnosed cardiac cause.",
"     </li>",
"     <li>",
"      Episodes that may be confused with syncope include disorders without impairment of consciousness (eg, falls) and disorders with partial or complete loss of consciousness such as seizures, metabolic abnormalities or anaphylaxis (",
"      <a class=\"graphic graphic_table graphicRef66333 \" href=\"UTD.htm?20/36/21068\">",
"       table 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/1\">",
"      Task Force for the Diagnosis and Management of Syncope, European Society of Cardiology (ESC), European Heart Rhythm Association (EHRA), et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 2009; 30:2631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/2\">",
"      Kapoor WN. Evaluation and outcome of patients with syncope. Medicine (Baltimore) 1990; 69:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/3\">",
"      Savage DD, Corwin L, McGee DL, et al. Epidemiologic features of isolated syncope: the Framingham Study. Stroke 1985; 16:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/4\">",
"      Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med 2002; 347:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/5\">",
"      Lipsitz LA. Syncope in the elderly. Ann Intern Med 1983; 99:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/6\">",
"      Freed LA, Eagle KA, Mahjoub ZA, et al. Gender differences in presentation, management, and cardiac event-free survival in patients with syncope. Am J Cardiol 1997; 80:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/7\">",
"      Schaal SF, Nelson SD, Boudoulas H, Lewis RP. Syncope. Curr Probl Cardiol 1992; 17:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/8\">",
"      Manolis AS, Linzer M, Salem D, Estes NA 3rd. Syncope: current diagnostic evaluation and management. Ann Intern Med 1990; 112:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/9\">",
"      Kapoor W, Karpf M, Levey GS. Issues in evaluating patients with syncope. Ann Intern Med 1984; 100:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/10\">",
"      Kapoor WN, Karpf M, Wieand S, et al. A prospective evaluation and follow-up of patients with syncope. N Engl J Med 1983; 309:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/11\">",
"      Chen L, Chen MH, Larson MG, et al. Risk factors for syncope in a community-based sample (the Framingham Heart Study). Am J Cardiol 2000; 85:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/12\">",
"      Alboni P, Brignole M, Menozzi C, et al. Diagnostic value of history in patients with syncope with or without heart disease. J Am Coll Cardiol 2001; 37:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/13\">",
"      Mathias CJ, Deguchi K, Schatz I. Observations on recurrent syncope and presyncope in 641 patients. Lancet 2001; 357:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/14\">",
"      Linzer M, Yang EH, Estes NA 3rd, et al. Diagnosing syncope. Part 1: Value of history, physical examination, and electrocardiography. Clinical Efficacy Assessment Project of the American College of Physicians. Ann Intern Med 1997; 126:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/15\">",
"      Linzer M, Yang EH, Estes NA 3rd, et al. Diagnosing syncope. Part 2: Unexplained syncope. Clinical Efficacy Assessment Project of the American College of Physicians. Ann Intern Med 1997; 127:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/16\">",
"      Kapoor WN, Peterson J, Wieand HS, Karpf M. Diagnostic and prognostic implications of recurrences in patients with syncope. Am J Med 1987; 83:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/17\">",
"      Kouakam C, Lacroix D, Klug D, et al. Prevalence and prognostic significance of psychiatric disorders in patients evaluated for recurrent unexplained syncope. Am J Cardiol 2002; 89:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/18\">",
"      Olshansky B, Mazuz M, Martins JB. Significance of inducible tachycardia in patients with syncope of unknown origin: a long-term follow-up. J Am Coll Cardiol 1985; 5:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/19\">",
"      Hamer AW, Rubin SA, Peter T, Mandel WJ. Factors that predict syncope during ventricular tachycardia in patients. Am Heart J 1984; 107:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/20\">",
"      Landolina M, Mantica M, Pessano P, et al. Impaired baroreflex sensitivity is correlated with hemodynamic deterioration of sustained ventricular tachycardia. J Am Coll Cardiol 1997; 29:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/21\">",
"      WAYNE HH. Syncope. Physiological considerations and an analysis of the clinical characteristics in 510 patients. Am J Med 1961; 30:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/22\">",
"      Brignole M, Menozzi C, Moya A, et al. Mechanism of syncope in patients with bundle branch block and negative electrophysiological test. Circulation 2001; 104:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/23\">",
"      Camm, AJ, Lau, CP. Syncope of undetermined origin: Diagnosis and management. Prog Cardiol 1988; 1:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/24\">",
"      Leitch JW, Klein GJ, Yee R, et al. Syncope associated with supraventricular tachycardia. An expression of tachycardia rate or vasomotor response? Circulation 1992; 85:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/25\">",
"      Doi A, Miyamoto K, Uno K, et al. Studies on hemodynamic instability in paroxysmal supraventricular tachycardia: noninvasive evaluations by head-up tilt testing and power spectrum analysis on electrocardiographic RR variation. Pacing Clin Electrophysiol 2000; 23:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/26\">",
"      Brembilla-Perrot B, Beurrier D, Houriez P, et al. Incidence and mechanism of presyncope and/or syncope associated with paroxysmal junctional tachycardia. Am J Cardiol 2001; 88:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/27\">",
"      Grech ED, Ramsdale DR. Exertional syncope in aortic stenosis: evidence to support inappropriate left ventricular baroreceptor response. Am Heart J 1991; 121:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/28\">",
"      Johnson AM. Aortic stenosis, sudden death, and the left ventricular baroceptors. Br Heart J 1971; 33:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/29\">",
"      Nienaber CA, Hiller S, Spielmann RP, et al. Syncope in hypertrophic cardiomyopathy: multivariate analysis of prognostic determinants. J Am Coll Cardiol 1990; 15:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/30\">",
"      Fananapazir L, Tracy CM, Leon MB, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation 1989; 80:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/31\">",
"      Narkiewicz K, Cooley RL, Somers VK. Alcohol potentiates orthostatic hypotension : implications for alcohol-related syncope. Circulation 2000; 101:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/32\">",
"      Rutan GH, Hermanson B, Bild DE, et al. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension 1992; 19:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/33\">",
"      Ray CA, Monahan KD. Aging attenuates the vestibulosympathetic reflex in humans. Circulation 2002; 105:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5272/abstract/34\">",
"      Sheldon R, Rose S, Ritchie D, et al. Historical criteria that distinguish syncope from seizures. J Am Coll Cardiol 2002; 40:142.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1049 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-37B631BF3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_9_5272=[""].join("\n");
var outline_f5_9_5272=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CAUSES OF SYNCOPE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Structural cardiac or cardiopulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Blood flow obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neurally-mediated syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Orthostatic hypotension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cerebrovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SYNCOPE OF UNKNOWN ORIGIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CAUSES OF NONSYNCOPAL ATTACKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Metabolic or toxic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1049\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1049|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/1/38941\" title=\"figure 1\">",
"      Incidence rates of syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/45/32477\" title=\"figure 2\">",
"      Etiology syncope men women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/2/23598\" title=\"figure 3\">",
"      Mortality with syncope by cause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1049|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/31/8701\" title=\"table 1\">",
"      Classification of syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/15/41211\" title=\"table 2\">",
"      Prevalence of syncope I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/38/32363\" title=\"table 3\">",
"      Prevalence of syncope II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/58/24491\" title=\"table 4\">",
"      Conditions incorrectly diagnosed as syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/36/21068\" title=\"table 5\">",
"      Symptoms and signs of anaphylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23223?source=related_link\">",
"      Approach to the patient with dizziness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10598?source=related_link\">",
"      Carotid sinus hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38888?source=related_link\">",
"      Differential diagnosis of anaphylaxis in children and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=related_link\">",
"      Evaluation of syncope in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28855?source=related_link\">",
"      Management of the patient with syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=related_link\">",
"      Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30551?source=related_link\">",
"      Natural history of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/9/4245?source=related_link\">",
"      Patient information: Syncope (fainting) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/5/36946?source=related_link\">",
"      Patient information: Syncope (fainting) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=related_link\">",
"      Reflex syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3878?source=related_link\">",
"      Sinus bradycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36471?source=related_link\">",
"      Subclavian steal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=related_link\">",
"      Third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_9_5273="Approach to the young athlete with acute knee pain or injury";
var content_f5_9_5273=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the young athlete with acute knee pain or injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/9/5273/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/9/5273/contributors\">",
"     Albert C Hergenroeder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/9/5273/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/9/5273/contributors\">",
"     Joseph Chorley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/9/5273/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/9/5273/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/9/5273/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/9/5273/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomy of the knee and evaluation of acute knee pain and injury in the young athlete will be presented here.",
"   </p>",
"   <p>",
"    Although acute and chronic injury are the most common causes of knee pain in young athletes, it is important to consider causes of knee pain that are unrelated to sports activity. These include malignancy, infection, arthritis, and referred pain from the hip (eg, slipped capital femoral epiphysis, Legg-Calv&eacute;-Perthes disease).",
"   </p>",
"   <p>",
"    The causes of knee pain, the evaluation of chronic knee pain, and the management of knee pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=see_link\">",
"     \"Traumatic causes of acute knee pain and injury in the young athlete\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=see_link\">",
"     \"Approach to the young athlete with chronic knee pain or injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=see_link\">",
"     \"Treatment of knee injuries in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The knee is the largest joint in the body [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. It is a modified hinge joint that maintains stability with considerable range of motion, primarily flexion. The stability is provided by the bones in conjunction with the articular capsule and its tendinous attachments, the collateral ligaments, and the intraarticular cruciate ligaments. The principal actions of the knee are flexion and extension, during which anterior-posterior movement and rotation also occur.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The transverse axis, around which flexion and extension occur, moves posteriorly during flexion and anteriorly during extension. Movement of the transverse axis permits the femoral condylar articular surface to be engaged during flexion without rolling off the back of the tibial plateau.",
"     </li>",
"     <li>",
"      The tibia rotates externally when going into extension and internally when going into flexion. Posterolateral rotatory stability is provided by multiple structures, including the lateral collateral ligament (LCL), arcuate ligament, the iliotibial band (ITB), and the biceps femoris and popliteus muscles. Posteromedial stability is provided by the medial collateral ligament (MCL), the oblique popliteal ligament, and the semimembranosus muscle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Articulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main bones of the knee are the femur, tibia, and patella. The fibular head lies within the capsule of the knee, but is not involved as a weight-bearing surface. There are three articulations in the knee: two tibiofemoral articulations and the patellofemoral articulation (",
"    <a class=\"graphic graphic_figure graphicRef65193 graphicRef51102 \" href=\"UTD.htm?23/56/24456\">",
"     figure 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The tibiofemoral articulation connects the distal femur, which broadens to form the medial and lateral femoral condyles, and the tibia. The tibia is flat, yet the concave menisci permit a tight articulation with the convex femoral condyles. The strength of the articulation is evident in full extension, when the femur and tibia are in close packed position, and rotation of the leg is possible only at the hip.",
"   </p>",
"   <p>",
"    The articular surfaces of the femoral condyles are covered with hyaline cartilage and separated by the intercondylar fossa. The medial condyle extends superiorly to form the medial epicondyle, which is the site of origin of the MCL, and, just proximal to that origin, the site of insertion of the adductor magnus muscle, a principal hip adductor. Posteriorly, the medial condyle is the site of origin of the medial head of the gastrocnemius muscle. The lateral femoral epicondyle is the site of origin of the LCL, and posteriorly, the site of attachment of the lateral head of the gastrocnemius muscle.",
"   </p>",
"   <p>",
"    The femoral condyles are separated by an intercondylar fossa, also called the femoral groove or femoral trochlea, which articulates with the patella. The patella is a sesamoid bone that develops in the quadriceps tendon; its function is to increase the mechanical advantage of the quadriceps. The rectus femoris and vastus intermedius muscles insert at the superior margin of the patella; the vastus lateralis and medialis muscles insert at the lateral and medial borders of the patella, respectively. The patellar tendon arises from the inferior patellar pole. The articular surface of the patella is round, with two facets separated by a vertical ridge. The vertical ridge articulates in the intercondylar fossa, mentioned above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Menisci",
"    </span>",
"    &nbsp;&mdash;&nbsp;The femoral condyles articulate with the two crescent-shaped menisci, which are attached at the peripheral rim of the tibia and deepen the fossa into which the condyles articulate. The menisci are thicker at their external margins, where they are attached to the rim of the tibia, and they thin to unattached edges at the interior of the articulation.",
"   </p>",
"   <p>",
"    The upper surfaces of the menisci are concave, corresponding to the convex shape of the femoral condyles, and the lower meniscal surfaces are flat, corresponding to the tibial surface. The peripheral one-third of the menisci is nourished directly by blood vessels, whereas the inner two-thirds are nourished by diffusion from the synovial fluid. Early in their embryologic development, the menisci have vasculature throughout their substance. Once a child begins to walk, weight is borne on the inner two-thirds of the menisci. The resultant pressure may lead to a recession of blood vessels, whereas the vasculature remains intact in the non-weightbearing peripheral one-third of the menisci.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lateral meniscus is circular and has more anterior-posterior mobility than the medial meniscus. It can move up to 12 mm during flexion and extension. During flexion, there is internal (medial) rotation of the tibia, accompanied by posterior excursion of the lateral meniscus. During extension, there is external (lateral) rotation of the tibia, accompanied by anterior movement of the lateral meniscus. The lateral meniscus is injured less commonly than the medial meniscus, perhaps because its mobility makes it less vulnerable to shearing and tearing forces.",
"     </li>",
"     <li>",
"      The medial meniscus is long and C-shaped. It is less mobile than the lateral meniscus because it is firmly attached to the posterior oblique ligaments and is held in place by the fibers of the MCL, which courses through it.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ligaments",
"    </span>",
"    &nbsp;&mdash;&nbsp;The knee contains two collateral and two cruciate ligaments (",
"    <a class=\"graphic graphic_figure graphicRef65193 graphicRef51102 \" href=\"UTD.htm?23/56/24456\">",
"     figure 1A-B",
"    </a>",
"    ). The collateral ligaments are strong bands at the sides of the knee that provide medial and lateral stability. They are located slightly behind the vertical axis of the knee so they are taut in extension, preventing hyperextension. They are most lax at 90 degrees of knee flexion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The medial or tibial collateral ligament (MCL) extends from the medial femoral epicondyle to the medial condyle of the tibia and the medial surface of the proximal femoral shaft. The MCL is the principal restraint to valgus rotation of the tibia relative to the femur [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/4\">",
"       4",
"      </a>",
"      ]. In adults, the ligament is approximately 8 to 9 cm long and it blends with the medial patellar retinaculum. Deep fibers extend onto the medial meniscus. The superficial fibers are separated by a bursa from the pes anserinus (the insertion of the gracilis, sartorius, and semitendinosus muscles).",
"     </li>",
"     <li>",
"      The lateral or fibular collateral ligament (LCL) is approximately 5 cm long and extends from the lateral femoral epicondyle to the insertion on the lateral head of the fibula. The LCL is the principal restraint to varus rotation of the tibia relative to the femur [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/5\">",
"       5",
"      </a>",
"      ]. The popliteus muscle passes deep to the LCL, and the biceps femoris splits on either side of its attachment to the fibular head.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cruciate ligaments are intraarticular, situated in a vertical plane between the condyles. The cruciate ligaments maintain the anterior-posterior stability of the femur on the tibia. They are most taut in extension, yet have varying degrees of tautness in all aspects of flexion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anterior cruciate ligament (ACL) originates from the nonarticular area of the tibia just anterior to the intercondylar eminence and courses superiorly to insert posteriorly on the medial aspect of the lateral femoral condyle. The ACL is the principal structure providing restraint to anterior displacement of the tibia relative to the femur [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/6\">",
"       6",
"      </a>",
"      ]. The ACL is taut in full extension as it fits into the posterior aspect of the intercondylar groove.",
"     </li>",
"     <li>",
"      The posterior cruciate ligament (PCL) extends from an area behind the intercondylar eminence, medial to the ACL, to insert on the medial side of the lateral femoral condyle. The PCL is the strongest and thickest of the knee ligaments. The PCL is the primary restraint to posterior translation of the tibia relative to the femur. It provides stability during terminal extension, as the femur internally rotates relative to the tibia, and is a secondary restraint to varus and valgus forces, in addition to preventing excess anterior-posterior movement of the femur on the tibia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Articular capsule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The articular capsule is intimately related to the ligaments and tendons that surround the knee. Posteriorly, the capsule originates in the femoral condyles and the intercondylar fossa. Inferiorly, it is overlain by the oblique popliteal ligament and inserts at the tibial condyles and the menisci. The external structures that reinforce the capsule include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The iliotibial band (ITB) (laterally)",
"     </li>",
"     <li>",
"      The medial and lateral patellar retinacula and patella (anteriorly)",
"     </li>",
"     <li>",
"      The oblique popliteal and arcuate ligaments (posteriorly)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As the semimembranosus tendon inserts into the groove at the back of the medial tibial condyle, there is an oblique lateral and superior extension that blends with a superficial component of the MCL and combines to form the posterior oblique or popliteal ligament, and courses to insert on the posterior lateral femoral condyle. The arcuate popliteal ligament arises from the back of the head of the fibula, arches upward and medially over the popliteus tendon, and fans out over the posterior aspect of the capsule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Muscles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vastus medialis and vastus lateralis muscles extend to the margins of the patella as the medial and lateral patellar retinacula, respectively. Medially, the retinaculum inserts on the shaft of the tibia; laterally, it blends with the ITB. The ITB is the terminal extension of the tensor fascia lata and the gluteus maximus, which fuse to form the ITB at the greater trochanteric bursa. The ITB inserts along the lateral proximal tibia at Gerdy's tubercle and at the fibular head.",
"   </p>",
"   <p>",
"    The popliteus muscle originates just inferior to the lateral femoral condyle. It runs deep to the LCL and is juxtaposed to the biceps femoris. It is reinforced in the posterolateral component of the joint by the arcuate ligament, with contributing fibers from the posterior capsule and fibular head. Fibers from the lateral meniscus and PCL contribute to the popliteus muscle. The insertion of the muscle is into the posterior superior part of the medial tibial condyle. It functions as an internal rotator of the tibia or lateral (external) rotator of the distal femur. It also protects the posterior horn of the lateral meniscus during flexion by pulling the horn posteriorly, and reinforces the PCL in preventing anterior translation of the femur during deceleration and downhill running.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Popliteal fossa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The popliteal fossa defines, in part, the posterior surface anatomy of the knee. The hamstring muscles (the semitendinosus, semimembranosus, and the biceps femoris), the primary flexors of the knee, form the superior margin of the popliteal fossa. From there, they diverge: the biceps femoris forms the lateral margin, and the semitendinosus and semimembranosus form the medial margin. The inferior border of the popliteal fossa is defined by the medial and lateral heads of the gastrocnemius muscle. The gastrocnemius muscle functions as a plantarflexor with the knee extended and assists with prevention of anterior translation of the femur on the tibia during extension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information obtained in the history will help to narrow the differential diagnosis in athletes who have knee complaints (",
"    <a class=\"graphic graphic_table graphicRef76993 graphicRef58127 \" href=\"UTD.htm?40/25/41373\">",
"     table 1A-B",
"    </a>",
"    ). The crucial elements of the history may vary, depending upon whether the complaints are acute or chronic. Acute complaints begin with a discrete event; chronic complaints have an insidious onset and a longer duration of symptoms. Past medical history, family history, and review of systems must be included to rule out other causes of joint pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    swelling (eg, arthritis or other rheumatologic disorder, gout, infection, hemoglobinopathy, bleeding disorder, or neoplasm).",
"   </p>",
"   <p>",
"    In the evaluation of a young athlete with acute knee pain or injury, it is important to determine [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Whether the complaint is acute or chronic. The evaluation of chronic complaints is discussed separately (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=see_link\">",
"       \"Approach to the young athlete with chronic knee pain or injury\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      What is the mechanism of injury (eg, a specific event versus repetitive activity)? If a specific event, are there videotapes or eyewitnesses who can describe what happened?",
"     </li>",
"     <li>",
"      Where is the pain?",
"     </li>",
"     <li>",
"      Are there mechanical symptoms (eg, locking, popping, or catching)?",
"     </li>",
"     <li>",
"      If there is swelling, when did it begin?",
"     </li>",
"     <li>",
"      Is there a sense of instability (ie, \"giving way\") or functional limitation (eg, is the athlete able to bear weight without pain)?",
"     </li>",
"     <li>",
"      Is there a history of previous knee injury? If so, how was it evaluated and treated?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The causes of acute and chronic knee pain and injury in young athletes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=see_link\">",
"     \"Traumatic causes of acute knee pain and injury in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mechanism of injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowing the mechanism of injury can help to localize the problem. Examples of the typical injuries with various mechanisms are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Knee dislocations are most common after high-velocity trauma; distraction forces may cause low-velocity dislocations.",
"     </li>",
"     <li>",
"      Compression forces are necessary to cause chondral and meniscal injury.",
"     </li>",
"     <li>",
"      Twisting forces cause meniscal and ACL injury [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyperextension can tear the ACL, the PCL, or both.",
"     </li>",
"     <li>",
"      Valgus forces can injure the ACL, MCL, and medial meniscus (the O'Donoghue triad), as well as the lateral meniscus.",
"     </li>",
"     <li>",
"      The PCL can be torn in a valgus or varus injury, but only after the first line of restraint is torn: the MCL in a valgus injury, and the LCL in a varus injury.",
"     </li>",
"     <li>",
"      Varus stress may cause injury to the LCL, cruciate ligaments, and superficial peroneal nerve.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the initial assessment of the young athlete with acute knee injury, it is important to identify those injuries or conditions that require immediate treatment by an orthopedic surgeon. As a general rule, athletes with these injuries have gross deformity, are at risk for neurovascular compromise, are unable to bear weight,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have rapid onset of hemarthrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/9\">",
"     9",
"    </a>",
"    ]. The injuries include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Open or structurally significant fractures",
"     </li>",
"     <li>",
"      Anterior or posterior knee dislocation (tibiofemoral dislocation)",
"     </li>",
"     <li>",
"      Multiple ligament injuries (eg, ACL and MCL, or LCL and either cruciate)",
"     </li>",
"     <li>",
"      Penetrating wounds",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many, but not all, of these injuries can be identified with gross inspection and a careful physical and neurovascular examination.",
"   </p>",
"   <p>",
"    Some knee dislocations may resolve spontaneously, and some fractures (as many as 67 percent in one study) may not be apparent on plain radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/9-15\">",
"     9-15",
"    </a>",
"    ]. Arthroscopy is a useful diagnostic and therapeutic tool in these patients, highlighting the need for early orthopedic surgery consultation when the diagnosis is in question",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obvious internal injury has occurred. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Arthroscopy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The knee should be exposed from the mid-thigh to the mid-tibia. The overall position of the leg and presence of gross deformities should be noted; comparison with the opposite knee may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/7\">",
"     7",
"    </a>",
"    ]. Gross deformity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    crepitation indicate fracture, dislocation, or ligamentous instability. The \"dimple sign\" is an important clue to posterolateral knee dislocation in which manual reduction should not be attempted. The \"dimple sign\" is a transverse groove in the skin at the medial joint line and is caused by invagination of the parts of the medial capsule and is an important clue to posterolateral knee dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/16\">",
"     16",
"    </a>",
"    ]. The skin and soft tissues should be inspected for erythema, swelling, and signs of trauma (eg, ecchymosis, laceration). Swelling within 24 hours of an acute knee injury suggests internal derangement [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Athletes with gross deformity or crepitation should have the knee immobilized as soon and as comfortably as possible, and they should be transferred to an emergency department for orthopedic consultation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=see_link&amp;anchor=H2#H2\">",
"     \"Traumatic causes of acute knee pain and injury in the young athlete\", section on 'Causes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The gait of the athlete in whom the initial evaluation does not suggest fracture or dislocation should be observed to see if he or she is able to bear weight. Movement of the knee is painful and guarded in patients with internal derangement (ie, fracture, chondral lesion, or injury to the cruciate ligaments, collateral ligaments, or menisci). Patients with these injuries usually have little spontaneous knee movement and are unable to bear weight, particularly if more than one structure is involved (eg, the medial meniscus and ACL).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neurovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurovascular status should be evaluated in all patients with acute knee injury. It must be evaluated without delay in those patients who have obvious knee deformity, or in whom there is any suspicion of knee dislocation, because of the potential for injury to the popliteal artery and peroneal nerve (",
"    <a class=\"graphic graphic_figure graphicRef50856 \" href=\"UTD.htm?15/9/15510\">",
"     figure 2",
"    </a>",
"    ). Immediate vascular surgery consultation is warranted for all patients in whom popliteal artery compromise is suspected. The neurovascular examination includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palpation of the dorsalis pedis and posterior tibial pulses to evaluate vascular integrity",
"     </li>",
"     <li>",
"      Assessment of sensation in the web space between the first and second toes, and ability to actively extend the great toe to evaluate deep peroneal nerve function",
"     </li>",
"     <li>",
"      Assessment of sensation of the plantar surface of the foot and ability to actively plantarflex the ankle to evaluate posterior tibial nerve function",
"     </li>",
"     <li>",
"      Ability to evert the ankle to evaluate superficial peroneal nerve function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The neurovascular examination should be repeated several times in the 24 hours after the injury, particularly in patients with knee instability. In a meta-analysis that evaluated the ability of the pulse examination to predict surgical arterial injury in patients with traumatic knee dislocation, the isolated finding of abnormal pedal pulses failed to detect as many as 36 percent of patients with arterial injuries requiring surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurovascular injury occurs most commonly in knee dislocations and displaced fractures. It is uncommon after ligamentous injury, even if two ligaments are injured. However, the varus stress caused by simultaneous injury to the LCL and one of the cruciate ligaments can be sufficient to injure the superficial peroneal nerve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For athletes who have no gross deformity and whose neurovascular integrity is intact, the physical examination should proceed by asking the patient to indicate, with one finger, the most painful spot. The distal femur, femoral condyles, proximal tibia, and entire patella should be palpated for possible fracture. Patients who have point tenderness or tenderness proximal to the joint lines (suggesting fracture) should have the extremity immobilized and be transported to an emergency department for further evaluation and management [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tenderness along the medial or lateral joint line (",
"    <a class=\"graphic graphic_picture graphicRef70461 \" href=\"UTD.htm?12/54/13152\">",
"     picture 1",
"    </a>",
"    ) may indicate medial or lateral meniscal tears, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/20\">",
"     20",
"    </a>",
"    ]. The accuracy of joint line tenderness in predicting associated meniscal lesions (confirmed at surgery) in knees with acute ACL ligament tears was evaluated in 173 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/21\">",
"     21",
"    </a>",
"    ]. The sensitivity and specificity of medial joint line tenderness in predicting medial meniscal injury were 45 percent and 35 percent, respectively. The sensitivity and specificity of lateral joint line tenderness in predicting lateral meniscal injury were 58 percent and 49 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Range of motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The range of motion (ROM) of the knee should be evaluated with full passive extension, the bounce home test, and the McMurray test.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gross laxity with passive maneuvers raises the suspicion of fracture, cruciate ligament injury, or other internal derangement.",
"     </li>",
"     <li>",
"      The bounce home test is another test of knee extension. It is performed with the patient supine. The knee is passively flexed to approximately 15 degrees and then permitted to fall into extension with gravity (",
"      <a class=\"graphic graphic_figure graphicRef55603 \" href=\"UTD.htm?35/24/36239\">",
"       figure 3",
"      </a>",
"      ). The test is positive if the knee does not fully extend (known as \"true locking\"). True locking can be caused by a displaced torn meniscal flap, a loose body, articular surface damage, or a torn ACL.",
"     </li>",
"     <li>",
"      The McMurray test involves passive flexion and extension of the knee with the hip in neutral position and the tibia internally and then externally rotated (",
"      <a class=\"graphic graphic_figure graphicRef57609 \" href=\"UTD.htm?6/33/6676\">",
"       figure 4",
"      </a>",
"      ). A modified McMurray test involves the same maneuvers of the knee and tibia, with the hip in internal, then in external, and, finally, in internal rotation. The McMurray test or modified McMurray test is positive when there is pain at the joint line, with or without a \"thunk,\" and limited ROM. A positive test implies meniscal injury. Full passive flexion of the knee must be achieved for optimal performance of the McMurray test and may be limited by the presence of a large knee effusion. If the test cannot be completed initially, it should be attempted after the effusion is reduced. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=see_link\">",
"       \"Treatment of knee injuries in the young athlete\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The McMurray test is specific, yet not sensitive for the detection of meniscal injuries, particularly in children [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/20,22-27\">",
"       20,22-27",
"      </a>",
"      ]. The sensitivity of the McMurray maneuver is limited, because the maneuver is incapable of trapping most anterior and anterolateral tears. The mean sensitivity of the test is 53 percent in the hands of orthopedists, with a mean sensitivity of 59 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/23\">",
"       23",
"      </a>",
"      ]. Thus, a negative test does not exclude a meniscal tear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ligaments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the ligaments includes palpation for tenderness and assessment of laxity with various maneuvers. These maneuvers, described below, can be performed gently to yield a preliminary diagnosis without causing great discomfort. Guarding limits the sensitivity of the examination. Tenderness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laxity suggests a ligamentous injury (sprain), the severity of which is graded according to the following system:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade 1: There is pain and no laxity with testing. There are microscopic tears in the ligament, yet the majority of the ligament is intact. An end point with provocative testing is present.",
"     </li>",
"     <li>",
"      Grade 2: There is a partial tear in the ligament, yet the majority of the ligament is intact. There is increased ligamentous laxity and an end point with provocative testing.",
"     </li>",
"     <li>",
"      Grade 3: There is complete disruption of the ligament. There is gross laxity with provocative testing and no end point.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The grades of sprains are easiest to determine in the immediate post-injury period before the onset of swelling and secondary muscle spasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Medial collateral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laxity of the MCL is evaluated with the",
"    <strong>",
"     valgus stress test",
"    </strong>",
"    &nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef77592 \" href=\"UTD.htm?40/37/41552\">",
"     picture 2",
"    </a>",
"    ). Laxity with the knee flexed to 30 degrees suggests an isolated MCL sprain. Laxity with valgus stress at 0 degrees of flexion (full extension) may indicate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fracture (eg, of the distal femoral epiphysis or physis)",
"     </li>",
"     <li>",
"      Posteromedial compartment involvement with a tear of the capsular component of the MCL in addition to the MCL",
"     </li>",
"     <li>",
"      Grade 3 ACL sprain in addition to grade 3 MCL sprain (since the ACL provides some medial stability in full extension). If it is clear from the examination that both the ACL and MCL are torn, the possibility of knee dislocation must be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Lateral collateral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laxity of the LCL is evaluated with the",
"    <strong>",
"     varus stress test",
"    </strong>",
"    &nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef69222 \" href=\"UTD.htm?36/46/37600\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laxity with varus testing at 30 degrees of flexion indicates an isolated LCL sprain.",
"     </li>",
"     <li>",
"      Gross instability on varus testing with the knee fully extended suggests disruption of the capsular component of the LCL, the midportion of the PCL, and posterolateral corner instability, including the arcuate popliteal complex.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another finding of grade 3 LCL sprains is that the normally taut LCL is absent when the patient sits with the involved knee in a figure-of-four position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Posterior cruciate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The posterior cruciate ligament is evaluated with the posterior sag test and the posterior drawer test. In the",
"    <strong>",
"     posterior sag test",
"    </strong>",
"    , the patient is supine, with hips flexed to 45 degrees, knees flexed to 90 degrees, and the feet flat on the table. In a positive test, the involved leg sags backward relative to the uninvolved leg. A positive",
"    <strong>",
"     posterior drawer test",
"    </strong>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef74928 \" href=\"UTD.htm?39/29/40415\">",
"     figure 5",
"    </a>",
"    ) also suggests PCL injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Anterior cruciate",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of three physical examination techniques can be employed to diagnose an ACL sprain: the anterior drawer test, the Lachman maneuver, and the pivot shift test.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anterior drawer test&nbsp;(",
"      <a class=\"graphic graphic_figure graphicRef53350 \" href=\"UTD.htm?41/61/42975\">",
"       figure 6",
"      </a>",
"      ) is positive, indicating an ACL sprain, if the affected tibia shifts excessively away from the femur. Complete tears are characterized by a difference of &gt;1 cm in tibial movement between the affected and unaffected knees. Partial tears are characterized by pain, loss of elasticity, and poor spring back.",
"      <br/>",
"      <br/>",
"      In a literature review of the accuracy of the clinical examination for meniscal or ligamentous knee injuries, the mean sensitivity and specificity of the anterior drawer test for ACL tears were 62 percent (range: 9 to 93 percent) and 67 percent (range: 23 to 100 percent), respectively, in the hands of orthopedists [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/23\">",
"       23",
"      </a>",
"      ]. The likelihood ratio for a positive test or negative test (odds that the condition is present with a positive or negative test) was 3.8 and 0.3, respectively.",
"     </li>",
"     <li>",
"      The Lachman test (",
"      <a class=\"graphic graphic_picture graphicRef65914 \" href=\"UTD.htm?16/54/17251\">",
"       picture 4",
"      </a>",
"      ) is similar to the anterior drawer test, except that the knee is only flexed to 20 degrees and the examiner's knee is placed under the patient's knee [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/28\">",
"       28",
"      </a>",
"      ]. The distal thigh is grasped above the patella with one hand and pressed down on the examiner's knee to stabilize the thigh, and the proximal tibia is grasped with the other hand to pull the tibia forward. As with the anterior drawer test, the Lachman test is positive if there is excessive anterior glide of the tibia compared with the opposite knee, or if there is no sharp endpoint to the anterior motion.",
"      <br/>",
"      <br/>",
"      The Lachman maneuver is a more sensitive indicator of ACL injury than is the anterior drawer test (mean sensitivity 84 percent in the hands of an orthopedist) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/16,22,23\">",
"       16,22,23",
"      </a>",
"      ]. It also is easier to perform in a patient who has acute knee injury and swelling.",
"     </li>",
"     <li>",
"      The pivot shift test&nbsp;(",
"      <a class=\"graphic graphic_figure graphicRef60176 \" href=\"UTD.htm?8/23/8563\">",
"       figure 7",
"      </a>",
"      ) is positive when there is a palpable shift as the knee is passively flexed from full extension and then extended from flexion. The pivot shift test may be a more sensitive test for the diagnosis of ACL injury than the anterior drawer and Lachman tests [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/29\">",
"       29",
"      </a>",
"      ]. However, it is difficult to perform in the acutely injured patient who has guarding and apprehension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The composite examination for an ACL tear using these three maneuvers, as performed by an orthopedic surgeon, is highly predictive, with a positive and negative likelihood ratio of 25 and 0.04, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/23\">",
"     23",
"    </a>",
"    ]. Data regarding the accuracy of these maneuvers in the hands of non-orthopedists are lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Muscles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's ability to contract the vastus medialis obliquus (VMO) muscle is evaluated by asking him or her to actively extend the knee. The muscle should be palpated for tone and inspected for bulk. Within a few days of disuse, VMO tone becomes notably reduced. Limited contraction of the VMO may be caused by effusion, pain, or mechanical obstruction; internal derangement should be suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Patella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with patellar dislocation and, to a lesser extent, with patellar subluxation, have pain in the medial patellar retinacular area and are apprehensive when the examiner tries to push the patella laterally (",
"    <a class=\"graphic graphic_figure graphicRef54035 \" href=\"UTD.htm?20/46/21216\">",
"     figure 8",
"    </a>",
"    ). Medial joint line tenderness (",
"    <a class=\"graphic graphic_figure graphicRef50856 \" href=\"UTD.htm?15/9/15510\">",
"     figure 2",
"    </a>",
"    ) and pain with valgus testing (",
"    <a class=\"graphic graphic_picture graphicRef77592 \" href=\"UTD.htm?40/37/41552\">",
"     picture 2",
"    </a>",
"    ) can cause confusion between the diagnoses of MCL sprain and patellar subluxation or dislocation. The apprehension sign should be negative in patients with MCL sprain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In acute knee injuries, a working diagnosis usually can be made on the basis of the clinical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/30\">",
"     30",
"    </a>",
"    ]. Plain radiographs (anterior-posterior [AP] and lateral views) usually are obtained if fractures are suspected. Sunrise views should be obtained after acute patellar dislocation to look for condylar fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/17\">",
"     17",
"    </a>",
"    ] and evaluate the posterior patella.",
"   </p>",
"   <p>",
"    The Ottawa knee rules, developed to aid in the diagnosis of knee fractures in adults, are 100 percent sensitive for the detection of clinically significant fractures (any bone fragment at least 5 mm in breadth or any avulsion fracture associated with complete disruption of tendons or ligaments) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. These rules state that radiographs of the knee should be obtained after acute injury",
"    <strong>",
"     only",
"    </strong>",
"    in patients who meet",
"    <strong>",
"     one or more",
"    </strong>",
"    of the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &ge;55 years",
"     </li>",
"     <li>",
"      Isolated tenderness of patella (with no other bony tenderness of the knee)",
"     </li>",
"     <li>",
"      Tenderness at the head of the fibula",
"     </li>",
"     <li>",
"      Inability to flex the knee to 90 degrees",
"     </li>",
"     <li>",
"      Inability to bear weight both immediately and in the emergency department for four steps, regardless of limp (ie, unable to transfer weight onto each lower limb two times)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a meta-analysis, the Ottawa knee rule was almost 100 percent sensitive for identifying patients who have knee fractures (99 percent, 95% CI 93-100 percent) and 49 percent specific (95% CI 43 to 51 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Ottawa knee rule was validated for children in a prospective, multicenter study that included 750 children aged 2 to 16 years who presented to the emergency department with a knee injury sustained in the previous seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/34\">",
"     34",
"    </a>",
"    ]. Radiographs were obtained in 670 children, and the remaining 80 children had a structured telephone interview 14 days after the injury. Clinically significant fractures included bone fragments of any size. The results were virtually identical to that in adults with a sensitive for identifying patients who have knee fractures of 100 percent (95% CI 95-100 percent) and a specificity of 43 percent (95% CI 39-47 percent). The clinical utility of the rules among children younger than five years of age may be limited.",
"   </p>",
"   <p>",
"    The development of hemarthrosis or effusion within 24 hours of injury also has been correlated with fractures after acute knee injury [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/10,35,36\">",
"     10,35,36",
"    </a>",
"    ] and may be another indication to obtain radiographs in the acute setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is not necessary in all patients with acute internal derangement, but should be used if the diagnosis is in question. As an example, if the history and physical examination findings are consistent with an isolated chronic MCL or meniscal injury, the patient should undergo rehabilitative therapy. If the patient responds as expected, MRI is not performed. However, if there is no improvement after an initial period of treatment, a noncontrast MRI may be indicated. This is particularly true if the plan is to undergo diagnostic arthroscopy only if the MRI is abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=see_link\">",
"     \"Treatment of knee injuries in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRI without contrast is approximately 90 percent accurate in identifying surgically confirmed ACL and meniscal injuries in adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/15,38,39\">",
"     15,38,39",
"    </a>",
"    ]. However, it is no more accurate, and is sometimes less accurate, than the physical examination of an experienced clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/20,40\">",
"     20,40",
"    </a>",
"    ]. For this reason, primary care physicians who are unskilled in the knee examination should consider referral of their patients with knee complaints to a sports medicine physician or orthopedic surgeon with training in sports medicine before making arrangements for an MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ARTHROSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthroscopy is the most accurate method of diagnosing the cause of internal derangement. False-positive results are rare, and with the exception of posterior meniscus injuries, false-negative results are also rare. Arthroscopy is used selectively, as an adjunct to the history, physical examination, and MRI when there is a diagnostic dilemma. The only absolute indication for arthroscopy is mechanical disruption of normal knee function. The decision to perform arthroscopy should be made as soon as possible after the injury presents to medical attention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute knee injury is common in young athletes. Proper diagnosis and prompt treatment are essential to ensure optimal outcome. Knowledge of the mechanism of injury and careful physical examination can help to pinpoint the diagnosis, which can be confirmed by radiographs, MRI,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arthroscopy.",
"   </p>",
"   <p>",
"    The following general recommendations can be made regarding the evaluation of acute knee pain and injury in the young athlete:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtain a history of the event from an eyewitness or videotape if possible.",
"     </li>",
"     <li>",
"      Athletes with gross deformity, neurovascular compromise, inability to bear weight, rapid onset of hemarthrosis, instability, or mechanical symptoms should have the joint immobilized as comfortably as possible and be transported to an emergency department for radiographs and orthopedic consultation.",
"     </li>",
"     <li>",
"      Neurovascular status should be serially evaluated in all acute knee injuries, particularly in patients with multiple injuries.",
"     </li>",
"     <li>",
"      Plain radiographs (AP, lateral, and possibly sunrise view) should be obtained in children according to the Ottawa Knee Rules. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Plain radiographs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If not obtained in the acute setting, radiographs should be obtained in patients who have swelling within 24 hours of injury or pain that persists for more than two days [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The hip and ankle should be evaluated in all patients with complaints of knee pain, particularly those who are skeletally immature [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5273/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Examination by an experienced clinician (eg, orthopedic surgeon, sports medicine physician) may be as helpful as an MRI.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Woodburne RT. Essentials of Human Anatomy, 5th, Oxford University Press, New York 1973.",
"    </li>",
"    <li>",
"     Reid, DC. Sports Injury Assessment and Rehabilitation, Churchill Livingstone, New York 1992.",
"    </li>",
"    <li>",
"     Zachazewski, JE, Magee, DJ, Quillen, WS. Athletic Injuries and Rehabilitation, WB Saunders, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/4\">",
"      Warren LA, Marshall JL, Girgis F. The prime static stabilizer of the medical side of the knee. J Bone Joint Surg Am 1974; 56:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/5\">",
"      Grood ES, Noyes FR, Butler DL, Suntay WJ. Ligamentous and capsular restraints preventing straight medial and lateral laxity in intact human cadaver knees. J Bone Joint Surg Am 1981; 63:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/6\">",
"      Butler DL, Noyes FR, Grood ES. Ligamentous restraints to anterior-posterior drawer in the human knee. A biomechanical study. J Bone Joint Surg Am 1980; 62:259.",
"     </a>",
"    </li>",
"    <li>",
"     Pasque CB, McGinnis DW. Knee. In: Care of the Young Athlete, American Academy of Orthopedic Surgeons and American Academy of Pediatrics, Elk Grove Village 2000. p.377.",
"    </li>",
"    <li>",
"     Knee and lower leg. In: Essentials of Musculoskeletal Care, 2nd, Greene WB (Ed), American Academy of Orthopedic Surgeons, Rosemont 2001. p.341.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/9\">",
"      Wessel LM, Scholz S, R&uuml;sch M. Characteristic pattern and management of intra-articular knee lesions in different pediatric age groups. J Pediatr Orthop 2001; 21:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/10\">",
"      Matelic TM, Aronsson DD, Boyd DW Jr, LaMont RL. Acute hemarthrosis of the knee in children. Am J Sports Med 1995; 23:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/11\">",
"      V&auml;h&auml;sarja V, Kinnuen P, Serlo W. Arthroscopy of the acute traumatic knee in children. Prospective study of 138 cases. Acta Orthop Scand 1993; 64:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/12\">",
"      Eiskjaer S, Larsen ST, Schmidt MB. The significance of hemarthrosis of the knee in children. Arch Orthop Trauma Surg 1988; 107:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/13\">",
"      Simonsen O, Jensen J, Mouritsen P, Lauritzen J. The accuracy of clinical examination of injury of the knee joint. Injury 1984; 16:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/14\">",
"      Bomberg BC, McGinty JB. Acute hemarthrosis of the knee: indications for diagnostic arthroscopy. Arthroscopy 1990; 6:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/15\">",
"      Lee K, Siegel MJ, Lau DM, et al. Anterior cruciate ligament tears: MR imaging-based diagnosis in a pediatric population. Radiology 1999; 213:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/16\">",
"      Liu SH, Osti L, Henry M, Bocchi L. The diagnosis of acute complete tears of the anterior cruciate ligament. Comparison of MRI, arthrometry and clinical examination. J Bone Joint Surg Br 1995; 77:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/17\">",
"      Hergenroeder, AC. Acute shoulder, knee, and ankle injuries Part 1: Diagnosis and management. Adolescent Health Update 1996; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/18\">",
"      Barnes CJ, Pietrobon R, Higgins LD. Does the pulse examination in patients with traumatic knee dislocation predict a surgical arterial injury? A meta-analysis. J Trauma 2002; 53:1109.",
"     </a>",
"    </li>",
"    <li>",
"     Price, CT, Flynn, JM. Management of fractures. In: Lovell and Winter's Pediatric Orthopedics, 6th edition, Morrissy, RT, Weinstein, SL (Eds), Lippincott, Williams, and Wilkins, Philadelphia 2006. p.1429.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/20\">",
"      Stanitski CL. Correlation of arthroscopic and clinical examinations with magnetic resonance imaging findings of injured knees in children and adolescents. Am J Sports Med 1998; 26:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/21\">",
"      Shelbourne KD, Martini DJ, McCarroll JR, VanMeter CD. Correlation of joint line tenderness and meniscal lesions in patients with acute anterior cruciate ligament tears. Am J Sports Med 1995; 23:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/22\">",
"      Malanga GA, Andrus S, Nadler SF, McLean J. Physical examination of the knee: a review of the original test description and scientific validity of common orthopedic tests. Arch Phys Med Rehabil 2003; 84:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/23\">",
"      Solomon DH, Simel DL, Bates DW, et al. The rational clinical examination. Does this patient have a torn meniscus or ligament of the knee? Value of the physical examination. JAMA 2001; 286:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/24\">",
"      Scholten RJ, Devill&eacute; WL, Opstelten W, et al. The accuracy of physical diagnostic tests for assessing meniscal lesions of the knee: a meta-analysis. J Fam Pract 2001; 50:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/25\">",
"      Stratford PW, Binkley J. A review of the McMurray test: definition, interpretation, and clinical usefulness. J Orthop Sports Phys Ther 1995; 22:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/26\">",
"      Micheli LJ, Foster TE. Acute knee injuries in the immature athlete. Instr Course Lect 1993; 42:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/27\">",
"      Iobst CA, Stanitski CL. Acute knee injuries. Clin Sports Med 2000; 19:621.",
"     </a>",
"    </li>",
"    <li>",
"     Reid DC. Sports Injury Assessment and Rehabilitation, Churchill Livingstone, New York 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/29\">",
"      Katz JW, Fingeroth RJ. The diagnostic accuracy of ruptures of the anterior cruciate ligament comparing the Lachman test, the anterior drawer sign, and the pivot shift test in acute and chronic knee injuries. Am J Sports Med 1986; 14:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/30\">",
"      Oberlander MA, Shalvoy RM, Hughston JC. The accuracy of the clinical knee examination documented by arthroscopy. A prospective study. Am J Sports Med 1993; 21:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/31\">",
"      Stiell IG, Greenberg GH, Wells GA, et al. Prospective validation of a decision rule for the use of radiography in acute knee injuries. JAMA 1996; 275:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/32\">",
"      Bachmann LM, Haberzeth S, Steurer J, ter Riet G. The accuracy of the Ottawa knee rule to rule out knee fractures: a systematic review. Ann Intern Med 2004; 140:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/33\">",
"      Stiell IG, Greenberg GH, Wells GA, et al. Derivation of a decision rule for the use of radiography in acute knee injuries. Ann Emerg Med 1995; 26:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/34\">",
"      Bulloch B, Neto G, Plint A, et al. Validation of the Ottawa Knee Rule in children: a multicenter study. Ann Emerg Med 2003; 42:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/35\">",
"      Pavlov H, Dalinka MK, Alazraki N, et al. Acute trauma to the knee. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000; 215 Suppl:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/36\">",
"      Fagan DJ, Davies S. The clinical indications for plain radiography in acute knee trauma. Injury 2000; 31:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/37\">",
"      Feller JA, Webster KE. Clinical value of magnetic resonance imaging of the knee. ANZ J Surg 2001; 71:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/38\">",
"      Cotten A, Delfaut E, Demondion X, et al. MR imaging of the knee at 0.2 and 1.5 T: correlation with surgery. AJR Am J Roentgenol 2000; 174:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/39\">",
"      Vincken PW, ter Braak BP, van Erkell AR, et al. Effectiveness of MR imaging in selection of patients for arthroscopy of the knee. Radiology 2002; 223:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/40\">",
"      Rose NE, Gold SM. A comparison of accuracy between clinical examination and magnetic resonance imaging in the diagnosis of meniscal and anterior cruciate ligament tears. Arthroscopy 1996; 12:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5273/abstract/41\">",
"      Stanitski CL. Pediatric and adolescent sports injuries. Clin Sports Med 1997; 16:613.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6514 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-CCB85E928E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_9_5273=[""].join("\n");
var outline_f5_9_5273=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Articulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Menisci",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Articular capsule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Popliteal fossa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mechanism of injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neurovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Range of motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ligaments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Medial collateral",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Lateral collateral",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Posterior cruciate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Anterior cruciate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Patella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      RADIOGRAPHIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ARTHROSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6514\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6514|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/59/23476\" title=\"figure 1A\">",
"      Anterior knee anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/6/20578\" title=\"figure 1B\">",
"      Sagittal knee anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/9/15510\" title=\"figure 2\">",
"      Neurovascular anatomy knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/24/36239\" title=\"figure 3\">",
"      Bounce home test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/33/6676\" title=\"figure 4\">",
"      McMurray test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/29/40415\" title=\"figure 5\">",
"      Posterior drawer test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/61/42975\" title=\"figure 6\">",
"      Anterior drawer test2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/23/8563\" title=\"figure 7\">",
"      Pivot shift test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/46/21216\" title=\"figure 8\">",
"      Patellar apprehension test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6514|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/54/13152\" title=\"picture 1\">",
"      Joint line palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/37/41552\" title=\"picture 2\">",
"      Valgus stress test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/46/37600\" title=\"picture 3\">",
"      Varus stress test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/54/17251\" title=\"picture 4\">",
"      Lachman test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6514|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/49/7965\" title=\"table 1A\">",
"      Differential diagnosis acute knee pain athlete A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/20/6476\" title=\"table 1B\">",
"      Differential diagnosis acute knee pain athlete B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=related_link\">",
"      Approach to the young athlete with chronic knee pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=related_link\">",
"      Traumatic causes of acute knee pain and injury in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=related_link\">",
"      Treatment of knee injuries in the young athlete",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_9_5274="Systemic onset juvenile idiopathic arthritis: Treatment";
var content_f5_9_5274=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systemic onset juvenile idiopathic arthritis: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/9/5274/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/9/5274/contributors\">",
"     Thomas JA Lehman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/9/5274/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/9/5274/contributors\">",
"     Marisa Klein-Gitelman, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/9/5274/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/9/5274/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/9/5274/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic onset juvenile idiopathic arthritis (also called systemic juvenile idiopathic arthritis [sJIA] and formerly called systemic onset juvenile rheumatoid arthritis or Still's disease) is a subset of juvenile idiopathic arthritis (JIA) that describes patients with fever, rash, and arthritis. It is sometimes called adult-onset Still's disease when it occurs in patients over the age of 16.",
"   </p>",
"   <p>",
"    The treatment options for systemic onset juvenile idiopathic arthritis are discussed in this review. The clinical manifestations, diagnosis, complications, and prognosis of systemic onset juvenile idiopathic arthritis are discussed separately, as are pauciarthritis and polyarthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=see_link\">",
"     \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39285?source=see_link\">",
"     \"Systemic onset juvenile idiopathic arthritis: Course, prognosis, and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=see_link\">",
"     \"Pauciarticular onset juvenile idiopathic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=see_link\">",
"     \"Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35717?source=see_link\">",
"     \"Classification of juvenile arthritis (JRA/JIA)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link&amp;anchor=H33#H33\">",
"     \"Hemophagocytic lymphohistiocytosis\", section on 'Macrophage activation syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) alone are effective for many children with systemic onset juvenile idiopathic arthritis (sJIA) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/1\">",
"     1",
"    </a>",
"    ]. Second line agents, such as glucocorticoids or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , are used if NSAIDs are ineffective. Biologic agents, such as monoclonal antibodies to interleukin-1 (IL-1) or IL-6, are effective in reducing clinical symptoms in patients with disease refractory to conventional therapy and more limited data suggest they are also beneficial when used early in the care of ill children with systemic onset JIA (ie, instead of glucocorticoids) once the diagnosis is confirmed.",
"   </p>",
"   <p>",
"    The initiation of any therapy in sJIA including NSAIDs, but probably not glucocorticoids, has been associated anecdotally with a transiently elevated risk of life-threatening macrophage activation syndrome (MAS). Accordingly, careful monitoring is essential. Since glucocorticoids represent a poor long-term therapeutic option because of associated toxicity, additional disease-modifying drugs are required in many patients to avoid the aggressive and often permanently disabling consequences of unremitting disease. Although the following discussion is an attempt to give useful guidelines, difficult cases of systemic onset JIA should be referred to an experienced pediatric rheumatologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link&amp;anchor=H33#H33\">",
"     \"Hemophagocytic lymphohistiocytosis\", section on 'Macrophage activation syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15847691\">",
"    <span class=\"h1\">",
"     INITIAL THERAPY FOR MILD TO MODERATE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drug (NSAID) monotherapy is the preferred initial treatment in children with possible systemic onset juvenile idiopathic arthritis with mild to moderate disease on presentation. While there is no formal definition of disease severity, we would categorize children with possible systemic onset JIA who have white blood cell counts in the range of 20,000 to 30,000 mm",
"    <sup>",
"     3",
"    </sup>",
"    , hemoglobin levels above 10",
"    <span class=\"nowrap\">",
"     gm/dL,",
"    </span>",
"    are not significantly discomforted by their symptoms, and have no evidence of macrophage activation syndrome (MAS), as having mild to moderate disease. In general, a trial of NSAIDs alone should last no more than 6 to 12 weeks; an additional agent is often added within two to four weeks in children who develop or continue to have significant symptoms despite use of NSAIDs. (See",
"    <a class=\"local\" href=\"#H15847723\">",
"     'Therapy for refractory disease/Initial therapy for severe disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    is inexpensive and was traditionally the NSAID of first choice. This is no longer true, due to the requirement of more frequent dosing, the increased need to monitor both serum salicylate levels and hepatic enzymes for evidence of hepatic toxicity, and the association of aspirin with Reye syndrome.",
"   </p>",
"   <p>",
"    All of the other traditional NSAIDs, and at least one of the COX-2 selective NSAIDs, have also been used for treating JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. None of these NSAIDs has shown any unique advantages for children with systemic onset JIA, based upon clinical experience. The possible exception is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    , which is effective for control of recalcitrant fever. However, indomethacin is rarely used for initial therapy due to an early report of association with death in a child with systemic onset JIA (although the exact cause of death was not clear) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/4\">",
"     4",
"    </a>",
"    ] and availability of numerous alternative NSAIDs. In addition, NSAIDs are not disease-modifying agents. Thus, a biologic agent or glucocorticoid, rather than indomethacin, is the preferred treatment option for control of persistent fever. (See",
"    <a class=\"local\" href=\"#H15847723\">",
"     'Therapy for refractory disease/Initial therapy for severe disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Use of any of the NSAIDs can be associated with hepatic irritation manifested by hepatic enzyme abnormalities and in rare cases possibly also disseminated intravascular coagulation (DIC) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/5\">",
"     5",
"    </a>",
"    ]. However, it is important to determine that the findings of DIC are not secondary to subclinical macrophage activation syndrome. NSAIDs may also irritate the kidneys, usually manifested as tubular interstitial disease with microscopic urine analysis changes, although patients can also develop edema, papillary necrosis, and hypertension. Thus, careful monitoring is required if NSAIDs are used. This includes complete blood counts, renal and liver function tests, and urine analyses within several weeks of starting the medication, and then every three to four months that the patient remains on a stable dose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link&amp;anchor=H33#H33\">",
"     \"Hemophagocytic lymphohistiocytosis\", section on 'Macrophage activation syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15847723\">",
"    <span class=\"h1\">",
"     THERAPY FOR REFRACTORY DISEASE/INITIAL THERAPY FOR SEVERE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have not responded to a trial of an NSAID alone during the acute phase of the illness, or whose initial symptoms include high fevers and painful polyarthritis, options include glucocorticoids, nonbiologic disease modifying antirheumatic drugs (DMARDs), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and biologic DMARDs, such as the IL-1 and IL-6 inhibitors. Glucocorticoids and the biologics are excellent antiinflammatory agents, but they do not directly provide pain relief, unlike NSAIDs. Thus, NSAIDs are often continued in conjunction with other agents for an extended period.",
"   </p>",
"   <p>",
"    Glucocorticoids provide rapid onset of action and almost uniform efficacy for severely ill children. Thus, historically, most pediatric rheumatologists have used glucocorticoids at this juncture, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    used as a steroid-sparing agent for longer-term control. However, most anticytokine (biologic) agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41796?source=see_link\">",
"     canakinumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    ) have more favorable side effect profiles than nonbiologic DMARDs (eg, methotrexate) or long-term use of glucocorticoids. In addition, anti-IL-1 and anti-IL-6 agents have shown good efficacy in randomized trials, in which they were primarily used as therapy for refractory disease. Thus, the preferred choice for refractory disease, and in some cases for initial therapy for severe disease, has shifted to the biologics agents (with or without glucocorticoids depending on severity). Inhibitors of IL-1 and IL-6 appear to be the most effective of the anticytokine agents for systemic symptoms (fever and rash), while inhibitors of tumor necrosis factor (TNF)-alpha can be helpful adjuncts for arthritis therapy. In general, a glucocorticoid should be added if there is not a prompt response to a biologic and vice versa, or if there is concern for incipient MAS. Both drugs are often continued until disease control is established and then the clinician may decide to gradually withdraw one or the other.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15847756\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials of glucocorticoids for the treatment of systemic onset JIA, although clinical experience offers general guidelines. As is generally the case, glucocorticoids should be used judiciously in systemic onset JIA to minimize their toxicity. They are typically used during the acute phase of the illness to preserve the ability to carry out activities of daily living, particularly in children who have not responded to NSAIDs.",
"   </p>",
"   <p>",
"    Every effort must be made to minimize the dosage and duration of therapy. Whenever possible, the dose of glucocorticoids should be kept below 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (or its equivalent) and the duration of therapy should be less than six months. Some clinicians use intermittent high dose intravenous glucocorticoids to reduce the toxicity of daily oral glucocorticoids or to treat severe anemia or pericarditis. However, this dosing regimen may be associated with an increased risk of infection or pancreatitis. It should also be kept in mind that the combination of glucocorticoids and NSAIDs can result in an increased risk of gastrointestinal toxicity due to their additive effect [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Optimally, a disease modifying agent more appropriate for long-term management (eg, a biologic agent or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) should be initiated soon after the child is stabilized in order to facilitate the timely withdrawal of glucocorticoids. (See",
"    <a class=\"local\" href=\"#H33080326\">",
"     'Methotrexate'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3029185\">",
"     'IL-1 inhibitors'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12929866\">",
"     'IL-6 inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15849649\">",
"    <span class=\"h2\">",
"     Anticytokine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic onset JIA is associated with increased circulating levels of multiple cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Experimental evidence supports the use of monoclonal antibodies or soluble receptors to block inflammatory cytokines in patients with systemic onset juvenile arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/9-16\">",
"     9-16",
"    </a>",
"    ]. Of these, the most efficacious biologic agents, based upon results from randomized trials, are those that block IL-1 or IL-6. Many pediatric rheumatologists are using one of these agents first for refractory disease, rather than a glucocorticoid. In addition, some are using them as initial therapy for severe disease after the diagnosis is confirmed (patients are treated with an NSAID prior to that). There are little published data regarding withdrawal of biologic agents in children with systemic onset JIA and no guidelines exist. Most pediatric rheumatologists gradually increase the dosing interval until they feel it is safe to stop therapy in children who appear to be in remission (on drug) for six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3029185\">",
"    <span class=\"h3\">",
"     IL-1 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;IL-1 is one of the predominant proinflammatory cytokines underlying the inflammatory symptoms of systemic arthritis. Thus, IL-1 inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    (recombinant IL-1 receptor antagonist) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41796?source=see_link\">",
"     canakinumab",
"    </a>",
"    (anti-IL-1-beta monoclonal antibody), are beneficial in some children with refractory systemic onset juvenile idiopathic arthritis. The IL-1 inhibitors, anakinra and canakinumab, are administered by periodic subcutaneous injection, whereas the IL-6 inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    is administered intravenously. Canakinumab is administered monthly, requiring many fewer injections than anakinra, which is administered daily. However, the anakinra dose can be adjusted more readily if the patient does not respond. The anti-IL-1 drugs do not cause the liver and bone marrow problems that are seen with the anti-IL-6 drugs and therefore do not have the same need for frequent monitoring. (See",
"    <a class=\"local\" href=\"#H12929866\">",
"     'IL-6 inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12929729\">",
"    <span class=\"h4\">",
"     Anakinra",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key role of IL-1 in systemic onset JIA and the clinical outcome of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    were documented in a study of nine patients with systemic onset JIA resistant to other therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/17\">",
"     17",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum from patients with systemic onset JIA upregulated the expression of genes from the IL-1",
"      <span class=\"nowrap\">",
"       cytokine/cytokine",
"      </span>",
"      receptor family and induced high levels of IL-1-beta production in peripheral blood mononuclear cells from healthy children.",
"     </li>",
"     <li>",
"      All nine patients became afebrile within the first week of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      therapy.",
"     </li>",
"     <li>",
"      Eight patients had active arthritis at the start of therapy. After two months of therapy, six had complete resolution and two had improvement in symptoms.",
"     </li>",
"     <li>",
"      All nine patients had normalization of elevated leukocyte and platelet counts, and eight of the nine patients had normalization of an elevated erythrocyte sedimentation rate after two months of therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent series have demonstrated in patients with established disease that IL-1 antagonism with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    can be very helpful in some and less so in others. This was illustrated in an Italian study of 22 patients (age range 9 months to 18 years) with systemic disease resistant to glucocorticoid therapy and one or more other agents [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/18\">",
"     18",
"    </a>",
"    ]. Ten patients had complete response with resolution of symptoms and normalization of serum acute phase reactants, and they were able to discontinue all other medications within four months of starting anakinra. Eleven patients had incomplete or no response and one patient could not be classified in regards to anakinra response. A similar experience was reported in other series [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/10,12,19-21\">",
"     10,12,19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     Anakinra",
"    </a>",
"    may be more effective if used early in the disease course, rather than as &ldquo;rescue&rdquo; therapy once other therapies have failed. One international group gathered 46 patients who had received anakinra as part of initial therapy for systemic onset JIA, including 10 treated with anakinra without glucocorticoids or other DMARDs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/22\">",
"     22",
"    </a>",
"    ]. Many patients avoided glucocorticoid therapy altogether, and chronic arthritis failed to develop in almost 90 percent of patients followed for more than six months (compared with 30 to 50 percent among historical controls).",
"   </p>",
"   <p>",
"    The optimal dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    remains undefined. In one series [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/22\">",
"     22",
"    </a>",
"    ], over 40 percent of children treated with less than 1.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    required dose escalation, suggesting that 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    is a reasonable starting range, although some rheumatologists favor higher doses in younger children who may have different drug pharmacokinetics [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Subsequent dose escalation to 4",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    or higher is necessary in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12929736\">",
"    <span class=\"h4\">",
"     Canakinumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results from two randomized trials, in addition to observational data, indicate that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41796?source=see_link\">",
"     canakinumab",
"    </a>",
"    (an anti-IL-1 beta monoclonal antibody) is an effective therapeutic option for patients with systemic onset JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the first trial, 84 children aged 2 to 19 years with active systemic JIA including both fever and arthritis were randomly assigned to a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41796?source=see_link\">",
"     canakinumab",
"    </a>",
"    (4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    subcutaneously) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/27\">",
"     27",
"    </a>",
"    ]. Concurrent treatment with another biologic agent was not allowed, but patients on background therapy of glucocorticoids, NSAIDs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    were allowed to enroll. There was a significant difference in the percent of patients with an adapted JIA American College of Rheumatology (ACR) 30 response between the canakinumab group and the placebo group (84 versus 10 percent, respectively). Two serious adverse events were reported in each group (macrophage activation syndrome [MAS] and varicella in the canakinumab group and MAS and gastroenteritis in the placebo group).",
"   </p>",
"   <p>",
"    The second trial included patients from the first trial (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41796?source=see_link\">",
"     canakinumab",
"    </a>",
"    responders and placebo group patients) plus additional patients (n = 100 in total) and had an initial open-label phase in which all patients were treated with canakinumab every four weeks for 12 to 32 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/27\">",
"     27",
"    </a>",
"    ]. In the randomized withdrawal phase, patients who had a sustained adapted JIA ACR 30 response or better and who were not on glucocorticoids or had been tapered to a stable glucocorticoid dose were either continued on canakinumab or placed on placebo. The rate of flares was significantly lower in the canakinumab group compared with the placebo group (26 versus 75 percent, respectively). In addition, inactive disease rates were higher at the end of the withdrawal phase in the canakinumab group compared with placebo (62 versus 34 percent). Four cases of MAS were reported in the open-label phase, and two in the withdrawal phase. Two patients with MAS died, one in the open-label phase and one from the placebo group in the withdrawal phase. There was no difference in the rate of serious adverse events between the two groups in the withdrawal phase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12929743\">",
"    <span class=\"h4\">",
"     Other IL-1 blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/21/16724?source=see_link\">",
"     Rilonacept",
"    </a>",
"    (an IL-1 receptor fusion protein) is available in the United States for treatment of autoinflammatory disorders, but its use in patients with systemic arthritis remains investigational [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12929866\">",
"    <span class=\"h3\">",
"     IL-6 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A human recombinant monoclonal antibody against the interleukin-6 receptor (MRA,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    ) that is administered intravenously appears to be effective in children with severe systemic arthritis that is resistant to conventional therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/11,15,30-34\">",
"     11,15,30-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    , 112 children aged 2 to 17 years with active systemic JIA (arthritis, with or without fevers and other systemic symptoms) of at least six months duration who had failed previous therapy with NSAIDs and glucocorticoids were treated with placebo or tocilizumab (12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for children &lt;30 kg or 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for children &ge;30 kg) intravenously every two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/34\">",
"     34",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At 12 weeks, improvement of ACR Pedi 30, 50, and 70 responses were seen in 85, 85, and 71 percent of patients, respectively, in the treatment group compared with 24, 11, and 8 percent of patients, respectively, in the placebo group.",
"     </li>",
"     <li>",
"      Adverse effects associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      included infections (eg, sinopulmonary infections, septic arthritis, varicella, gastroenteritis), macrophage activation syndrome, neutropenia, and elevated liver function tests and cholesterol. In addition, serious and life-threatening infusion reactions have occurred.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     Tocilizumab",
"    </a>",
"    was approved by the FDA for treatment of systemic JIA in children based upon these results. The long-term safety and efficacy of this drug is still unknown. Recommended lab monitoring includes neutrophil and platelet counts and liver enzyme",
"    <span class=\"nowrap\">",
"     (AST/ALT)",
"    </span>",
"    levels at the time of the second infusion and then every two to four weeks, and lipid monitoring four to eight weeks after initiation of therapy and then approximately every 24 weeks. The appropriate role for tocilizumab in the treatment of children with systemic onset JIA should become clearer as pediatric rheumatologists gain experience with this agent. Tocilizumab appears particularly useful in patients with refractory chronic arthritis, though it is also effective for systemic symptoms (fever and rash).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15849670\">",
"    <span class=\"h3\">",
"     TNF-alpha inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several anticytokine agents that inhibit TNF-alpha activity are available, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      , a soluble p75 TNF-alpha receptor fusion protein that binds TNF-alpha, has been widely tested in systemic onset JIA. However, it may provide only limited and unpredictable benefits in this disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/35-40\">",
"       35-40",
"      </a>",
"      ]. This was illustrated in a questionnaire survey of pediatric rheumatologists that identified 82 patients with systemic arthritis treated with etanercept for a mean of 25 months [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/36\">",
"       36",
"      </a>",
"      ]. Response to treatment was assessed as a reduction in disease activity (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose, active joint count, clinician global assessment, and laboratory measure of acute phase reactants). Almost half of the patients (45 percent) had a poor response to treatment (&lt;30 percent reduction), 22 percent a fair to good response (30 to &lt;70 percent reduction), and 33 percent an excellent response (&gt;70 percent reduction). There were 32 adverse events reported, including two cases of macrophage activation syndrome (MAS). Adding to the uncertainty of the benefit or harm of etanercept, it has been reported both as a cause of [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/41\">",
"       41",
"      </a>",
"      ], and a treatment for [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/42\">",
"       42",
"      </a>",
"      ], MAS in children with systemic onset disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39285?source=see_link&amp;anchor=H401611#H401611\">",
"       \"Systemic onset juvenile idiopathic arthritis: Course, prognosis, and complications\", section on 'Macrophage activation syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link&amp;anchor=H33#H33\">",
"       \"Hemophagocytic lymphohistiocytosis\", section on 'Macrophage activation syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      , monoclonal antibodies to TNF-alpha, also have been used with varying success in children with systemic onset JIA [",
"      <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/39\">",
"       39",
"      </a>",
"      ]. These agents have been effective in patients who failed to respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      , although there are limited published data.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, TNF inhibitors are more beneficial for children with isolated polyarthritis than in those with systemic onset JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. This difference may be due to different cytokines underlying the inflammatory response for each respective disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/37\">",
"     37",
"    </a>",
"    ]. IL-6 and IL-1 rather than TNF-alpha appear to be the predominant proinflammatory cytokines in systemic onset JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/8,17,43\">",
"     8,17,43",
"    </a>",
"    ]. Thus, biologic agents that target IL-1 and IL-6 activity, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , appear to be more successful in treating patients with systemic onset JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/9-12,30\">",
"     9-12,30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3029185\">",
"     'IL-1 inhibitors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12929866\">",
"     'IL-6 inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Alternatively, the fixed doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    that have been used may be inadequate to inhibit TNF sufficiently to produce a robust response in systemic onset JIA. Other TNF inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , offer a wider range of dosing options, and indeed high doses of this medication may be more effective for treating systemic onset JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/44\">",
"     44",
"    </a>",
"    ]. Some pediatric rheumatologists now prefer infliximab, 5 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every four to six weeks, over other anti-TNF agents.",
"   </p>",
"   <p>",
"    Citing concerns about signals of a possible spike in the incidence of lymphoma and other malignancies in children treated with biologic response modifiers, the US Food and Drug Administration (FDA) performed a Safety Review of TNF inhibitors. They concluded that there is an increased risk of lymphoma and other cancers, based upon events recorded predominantly in patients treated for inflammatory bowel disease, associated with the use of these drugs in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/45\">",
"     45",
"    </a>",
"    ]. However, a study published subsequently to this review found that although children with JIA have an increased risk of malignancy, medications used for JIA, including TNF inhibitors, were not significantly associated with additional malignancy risk [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, there may be an increased risk of fungal infections with the use of TNF inhibitors. An FDA alert highlighted this potential risk, especially in areas endemic for histoplasmosis, such as the Ohio and Mississippi River valleys [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/47\">",
"     47",
"    </a>",
"    ]. Clinicians in areas of endemic fungal infections should monitor their patients appropriately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15849688\">",
"    <span class=\"h3\">",
"     Thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    is a unique agent which is effective in both suppressing the production of cytokines such as TNF-alpha and IL-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], and in blocking angiogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/48\">",
"     48",
"    </a>",
"    ]. Case reports and small series suggest that thalidomide is an effective medication for children with systemic onset JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. With the advent of effective IL-1 and IL-6 inhibitors, however, thalidomide and its derivatives should be reserved for children in whom the biologics are not options. (See",
"    <a class=\"local\" href=\"#H3029185\">",
"     'IL-1 inhibitors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12929866\">",
"     'IL-6 inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Neuropathy and sedative effects are often dose limiting. This agent is an infamous teratogen and clinical use is controlled. Effective contraception is a prerequisite for use in girls of child bearing age. Despite these cautions, it has been dramatically effective for some children who have failed other therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    may be especially important in countries where biologic agents are not available because of cost issues. Revlimid (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ) is an alternative agent related to thalidomide that has been proposed to have a lower incidence of side effects, but there are no published trials of its use in systemic onset JIA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33080326\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive clinical experience suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is effective for the control of disease manifestations in many children with systemic onset JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/51\">",
"     51",
"    </a>",
"    ], although results from one small randomized trial showed no difference in overall improvement in the methotrexate group compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/52\">",
"     52",
"    </a>",
"    ]. Methotrexate has traditionally been used as a steroid-sparing agent. With the advent of anti-IL-1 and anti-IL-6 therapies, the role of methotrexate is being reconsidered.",
"   </p>",
"   <p>",
"    Hepatic toxicity may occur with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy, but does not seem to be any more frequent than expected with the use of methotrexate in other subtypes of JIA. Appropriate clinical and laboratory monitoring is essential for patients treated with methotrexate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=see_link\">",
"     \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The general range in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is prescribed for JIA is an oral dose of up to 25 to 30",
"    <span class=\"nowrap\">",
"     <strong>",
"      mg/m",
"     </strong>",
"     <strong>",
"      <sup>",
"       2",
"      </sup>",
"     </strong>",
"    </span>",
"    (0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    per week, with a",
"    <strong>",
"     maximum dose of 25 mg",
"    </strong>",
"    per week. Above 15 to 20",
"    <span class=\"nowrap\">",
"     <strong>",
"      mg/m",
"     </strong>",
"     <strong>",
"      <sup>",
"       2",
"      </sup>",
"     </strong>",
"    </span>",
"    (roughly 0.5",
"    <span class=\"nowrap\">",
"     mg/kg),",
"    </span>",
"    oral absorption is unreliable and parenteral administration may be advantageous [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/53\">",
"     53",
"    </a>",
"    ]. Oral doses of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or more may be beneficial in a selected subgroup of patients, but do not improve the response in the majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/54\">",
"     54",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    should be given to minimize the gastrointestinal side effects associated with methotrexate therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17162?source=see_link&amp;anchor=H6#H6\">",
"     \"Polyarticular onset juvenile idiopathic arthritis: Management\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272251835\">",
"    <span class=\"h2\">",
"     Leflunomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     Leflunomide",
"    </a>",
"    is an isoxazole derivative that has effects on many components of immune and inflammatory responses. In case reports and small series, leflunomide has been used successfully to treat some patients with poor response to, or side effects from,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. However, leflunomide was less effective than methotrexate and had a similar side effect profile in one head-to-head randomized trial of 94 patients with polyarticular JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1645837\">",
"    <span class=\"h2\">",
"     B cell targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    , a B cell depleting monoclonal anti-CD20 antibody, has been used for severe, multiple drug-resistant, systemic onset JIA with success at the case-report level [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link&amp;anchor=H2#H2\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15850522\">",
"    <span class=\"h2\">",
"     Cytotoxic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    have been used in the treatment of systemic onset JIA with varying success. Azathioprine and cyclophosphamide are effective for only a subset of children with systemic onset JIA; however, they may be associated with sustained improvement in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/59\">",
"     59",
"    </a>",
"    ]. It is not clear yet what factors lead to responsiveness in this subset of children. The use of these drugs is primarily restricted to a small group of children who have failed all available biologic agents.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     Chlorambucil",
"    </a>",
"    is the historic drug of choice in the treatment of amyloidosis complicating juvenile chronic arthritis, and is continued for one year after the disease becomes inactive [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/60\">",
"     60",
"    </a>",
"    ]. However, amyloidosis is a rarely observed complication of systemic onset JIA, and the advent of newer biologic agents places in question the role of this agent, particularly in view of its association with the development of acute myelogenous leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anticytokine therapies, particularly IL-1 inhibitors, are generally preferred over cytotoxic drugs. Cytotoxic medications are generally reserved for children who have progressive disease despite extensive use of less toxic medications. Leukopenia, infections, the risk of sterility, and the risk of subsequent neoplastic disease limit their utility. Accordingly,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    only should be used by experienced clinicians after all reasonable alternatives have been considered [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H15849649\">",
"     'Anticytokine therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15850595\">",
"    <span class=\"h1\">",
"     OTHER AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sulfasalazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    may be beneficial in selected cases, although it is associated with toxicity in up to 75 percent of children with systemic onset JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/62\">",
"     62",
"    </a>",
"    ]. The usual dosage range is 30 to 70",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (up to 2",
"    <span class=\"nowrap\">",
"     grams/day)",
"    </span>",
"    divided twice daily. With the increasing array of safer and more effective agents, sulfasalazine should be avoided if at all possible in patients with systemic onset JIA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hydroxychloroquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    (Plaquenil) has been used in many children with systemic onset JIA. However, its efficacy is uncertain, and with the advent of biologics, there is little role for hydroxychloroquine in the management of systemic onset JIA. Many children improve while receiving hydroxychloroquine, but this drug is almost never used alone. It is therefore difficult to ascertain what proportion of the improvement in such cases may be ascribed to hydroxychloroquine [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/63\">",
"     63",
"    </a>",
"    ]. It is important to keep the dose of hydroxychloroquine under 6.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in order to minimize the risk of potentially irreversible retinal toxicity, particularly in patients who weigh less than (or whose ideal body weight is less than) 31 kg. For these smaller patients, caregivers must carefully divide 200 mg tablets as accurately as possible to administer the appropriate dosage. Pharmacists can provide hydroxychloroquine in a liquid form for small children who are unwilling or unable to swallow tablets, or if it is too difficult to split the tablets to reliably administer the correct dosage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin (IVIG) was described as highly effective in preliminary trials in patients with systemic onset JIA, but failed to achieve statistically significant benefit in controlled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Its apparent failure in this disorder (as opposed to its clear benefit in Kawasaki disease) may be related to the chronic nature of JIA. Overall, the limited benefit, high cost, and potential toxicity suggest that IVIG has no real role in the management of systemic onset JIA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    has received increased attention over the past few years in systemic onset JIA. There were several promising reports, but subsequent case reports found it to have only limited success, with the exception of its potential usefulness in the treatment of",
"    <span class=\"nowrap\">",
"     DIC/macrophage",
"    </span>",
"    activation syndrome (MAS) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39285?source=see_link\">",
"     \"Systemic onset juvenile idiopathic arthritis: Course, prognosis, and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link&amp;anchor=H33#H33\">",
"     \"Hemophagocytic lymphohistiocytosis\", section on 'Macrophage activation syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9243469\">",
"    <span class=\"h1\">",
"     COMBINATION DRUG THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a growing consensus that combination drug regimens may provide the greatest potential benefit for children with severe systemic onset JIA. Combinations of NSAIDs with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and other agents are under study in small series. Definitive reports of their efficacy are not yet available. Nevertheless, early and aggressive intervention with combination drug regimens including biologics appears to offer the best hope for those with difficult to control systemic onset JIA.",
"   </p>",
"   <p>",
"    However, caution must be exercised when a combination of agents is used. As an example, the combination of the IL-1 inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    with anti-TNF agents significantly increases the incidence of infection, which resulted in a US Food and Drug Administration (FDA) black box warning in the package inserts of these medications. Thus, larger clinical trials are needed in order to identify combination drug therapies that are effective and safe, as well as to determine dosages and duration of therapy.",
"   </p>",
"   <p>",
"    Children receiving combination therapy are best managed by pediatric rheumatologists, who are familiar with the treatment of severe childhood arthritis, because of the potential toxicity of these drugs and the unpredictability of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     HEMATOPOIETIC CELL TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT) may represent an alternative for children with relentless disease that is uncontrolled despite the use of multiple drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An observational study of autologous stem cell transplantation (ASCT) included 34 children treated at several European centers, 29 of whom had systemic onset disease and the others severe polyarticular involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/70\">",
"     70",
"    </a>",
"    ]. The following findings were noted at follow-up that ranged from 12 to 60 months:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug free remission was noted in 18 of 34 (53 percent), improvement occurred in another six, while in seven children, there was no benefit.",
"     </li>",
"     <li>",
"      Infectious complications following the transplant were frequent and included septicemia, disseminated varicella-zoster, cytomegalovirus, legionella, hepatitis A, herpes simplex virus, and toxoplasma infections. Three children died due to infectious complications or due to macrophage activation syndrome (acquired or secondary hemophagocytic lymphohistiocytosis) that might have been infection related. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link&amp;anchor=H33#H33\">",
"       \"Hemophagocytic lymphohistiocytosis\", section on 'Macrophage activation syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a subsequent report from the same European centers involving many of the same subjects, 18 patients with systemic onset disease and the four with polyarticular disease underwent ASCT between 1997 and 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/71\">",
"     71",
"    </a>",
"    ]. Two died early in follow-up from macrophage activation syndrome (MAS) and the remaining 20 patients were observed over a median period of 80 months with the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eight patients were in drug-free complete remission and seven in partial remission with a positive response to reinstitution of second line agents (ie, glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In five patients, there was no benefit and two of the patients subsequently died from infections that developed after restarting immunosuppressive medication.",
"     </li>",
"     <li>",
"      During this trial the induction protocol in preparation for ASCT was modified in 1999 to decrease the depletion of T cells, because of the early deaths attributed to macrophage activation syndrome (MAS). No ASCT-related deaths were observed in the 11 patients who received the modified conditioning regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In both studies, many patients did not receive anti-TNF therapies prior to ASCT. Those who had tried and failed anti-TNF agents were among those with a good outcome following the transplant procedure. Accordingly, failure to respond to anti-TNF agents is now a criterion for inclusion in trials of HCT for refractory JIA.",
"   </p>",
"   <p>",
"    There is continued interest in the use of both ASCT and allogeneic stem cell transplantation for severe resistant systemic onset JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. However, the protocol for transplanting children with this disease is still evolving and the procedure still carries a high mortality rate for an illness that typically does not have a fatal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?5/9/5274/abstract/72\">",
"     72",
"    </a>",
"    ]. Further, given the additional anticytokine therapies available, HCT should be restricted to only the most severely affected children refractory to anticytokine therapy and in whom the risk of death is deemed to be acceptable. It is hoped that over time safer and more effective protocols for HCT will become available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15850614\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The propensity of children with systemic onset JIA to develop sudden, severe, and life-threatening drug-induced toxicity must be carefully balanced against the aggressive and often permanently disabling nature of unremitting disease. Thus, patients who present with severe systemic onset JIA or who are refractory to NSAIDs should be referred to an experienced pediatric rheumatologist for management if possible. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with mild to moderate, nondisabling symptoms, we suggest a nonsteroidal antiinflammatory drug (NSAID) other than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      as initial therapy for systemic onset juvenile idiopathic arthritis (JIA) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). All of the NSAIDs appear to have equivalent efficacy, based upon clinical experience. In general, a trial of NSAIDs alone should last no more than 6 to 12 weeks; an additional agent is often added sooner in children who develop or continue to have significant symptoms despite use of NSAIDs. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Nonsteroidal antiinflammatory drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Historically most pediatric rheumatologists have added a glucocorticoid to NSAID therapy in patients who have not responded to a trial of an NSAID alone or who have severe disease on initial presentation. However, long-term use of glucocorticoids is associated with a high frequency of side effects. In addition, the biologic agents, such as monoclonal antibodies to interleukin-1 (IL-1) or IL-6, are effective in reducing clinical symptoms in patients with disease refractory to NSAID and glucocorticoid therapy, and more limited data suggest they are also beneficial when used early in the care of children with severe systemic onset JIA (ie, instead of glucocorticoids) once the diagnosis is confirmed. Thus, the side effects of glucocorticoids must be weighed against the cost of the biologic agents. The decision to initiate therapy with a biologic agent first and the choice of biologic agent must be made by the individual treating clinician based upon their experience and the wishes of the patient and family after the risks and benefits are explained. (See",
"      <a class=\"local\" href=\"#H15847723\">",
"       'Therapy for refractory disease/Initial therapy for severe disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have not responded to a trial of an NSAID alone, or whose initial symptoms include high fevers and painful polyarthritis (severe disease), we suggest adding one of the biologic agents, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41796?source=see_link\">",
"       canakinumab",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      , rather than glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The anti-IL-1 agents, anakinra and canakinumab, have the advantage of being administered by periodic subcutaneous injection while the anti-IL-6 agent, tocilizumab, is administered intravenously. Anakinra is initially prescribed at a dose of 1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily, but doses as high as 8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      have been used in children with cryopyrin-associated diseases. Canakinumab is usually given as 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      monthly in children less than 40 kg, but the full vial of 150 mg is given to children over 40 kg. Tocilizumab is typically given monthly at a dose of 12",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for children who weigh less than 30 kg and 8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for those who weigh more. (See",
"      <a class=\"local\" href=\"#H15847723\">",
"       'Therapy for refractory disease/Initial therapy for severe disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3029185\">",
"       'IL-1 inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12929866\">",
"       'IL-6 inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest adding a glucocorticoid if there is not a prompt response to a biologic agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). While the definition of a prompt response will differ from center to center, few pediatric rheumatologists would wait more than a week before adding a glucocorticoid in the face of continued polyarthritis, fever, and rash, and all would add a glucocorticoid sooner if there was evidence of macrophage activation syndrome. Both the glucocorticoid and the biologic are often continued until disease control is established and then the clinician may decide to gradually withdraw one or the other. The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose should be limited to 0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      if possible, although doses as high as 2",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      or pulsed dose \"bolus therapy&rdquo; may be required in severe cases. We suggest adding a second line glucocorticoid-sparing agent, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , as soon as the child has stabilized on glucocorticoids and before significant glucocorticoid side effects occur (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15847756\">",
"       'Glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33080326\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematopoietic cell transplantation (HCT) may represent an alternative for children with relentless disease that is uncontrolled despite the use of multiple drugs. However, it remains an experimental and rarely chosen option, in view of its relatively unfavorable risk to benefit ratio compared with modern biologic response modifiers. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/1\">",
"      Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/2\">",
"      Ilowite NT. Current treatment of juvenile rheumatoid arthritis. Pediatrics 2002; 109:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/3\">",
"      Celebrex gets committee nod for juvenile arthritis, but safety registry urged. \"The Pink Sheet\" 2006; 68(49):7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/4\">",
"      Jacobs JS. Sudden death in arthritic children receiving large doses of indomethacin. JAMA 1967; 199:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/5\">",
"      Sbarbaro JA, Bennett RM. Aspirin hepatotoxicity and disseminated intravascular coagulation. Ann Intern Med 1977; 86:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/6\">",
"      Goldstein JL. Who needs prophylaxis of nonsteroidal anti-inflammatory drug-induced ulcers and what is optimal prophylaxis? Eur J Gastroenterol Hepatol 2000; 12 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/7\">",
"      Muzaffer MA, Dayer JM, Feldman BM, et al. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. J Rheumatol 2002; 29:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/8\">",
"      de Benedetti F, Massa M, Robbioni P, et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991; 34:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/9\">",
"      Elliott MJ, Woo P, Charles P, et al. Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). Br J Rheumatol 1997; 36:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/10\">",
"      Irigoyen PI, Olson J, Horn C, et al. Treatment of systemic onset juvenile rheumatoid arthritis with anakinra. Arthritis Rheum 2004; 50:S437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/11\">",
"      Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005; 52:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/12\">",
"      Henrickson M. Efficacy of anakinra in refractory systemic arthritis. Arthritis Rheum 2004; 50:S438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/13\">",
"      M&uuml;ller K, Herner EB, Stagg A, et al. Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Br J Rheumatol 1998; 37:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/14\">",
"      Mangge H, Schauenstein K. Cytokines in juvenile rheumatoid arthritis (JRA). Cytokine 1998; 10:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/15\">",
"      Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005; 7:R1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/16\">",
"      Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010; 11:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/17\">",
"      Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/18\">",
"      Gattorno M, Piccini A, Lasigli&egrave; D, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008; 58:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/19\">",
"      Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004; 31:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/20\">",
"      Lequerr&eacute; T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008; 67:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/21\">",
"      Zeft A, Hollister R, LaFleur B, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 2009; 15:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/22\">",
"      Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011; 63:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/23\">",
"      Ilowite N, Porras O, Reiff A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009; 28:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/24\">",
"      Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/25\">",
"      Dhimolea E. Canakinumab. MAbs 2010; 2:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/26\">",
"      Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012; 64:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/27\">",
"      Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/28\">",
"      Breda L, Del Torto M, De Sanctis S, Chiarelli F. Biologics in children's autoimmune disorders: efficacy and safety. Eur J Pediatr 2011; 170:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/29\">",
"      Molt&oacute; A, Oliv&eacute; A. Anti-IL-1 molecules: new comers and new indications. Joint Bone Spine 2010; 77:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/30\">",
"      Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/31\">",
"      Yokota S, Miyamae T, Imagawa T, et al. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol 2005; 28:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/32\">",
"      Nishimoto N. Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther 2010; 87:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/33\">",
"      Inaba Y, Ozawa R, Imagawa T, et al. Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab treatment. Ann Rheum Dis 2011; 70:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/34\">",
"      De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/35\">",
"      Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/36\">",
"      Kimura Y, Pinho P, Walco G, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005; 32:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/37\">",
"      Eberhard BA, Ilowite NT. Response of systemic onset juvenile rheumatoid arthritis to etanercept: is the glass half full or half empty? J Rheumatol 2005; 32:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/38\">",
"      Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009; 68:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/39\">",
"      Russo RA, Katsicas MM. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol 2009; 36:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/40\">",
"      Otten MH, Prince FH, Armbrust W, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 2011; 306:2340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/41\">",
"      Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 2003; 30:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/42\">",
"      Prahalad S, Bove KE, Dickens D, et al. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 2001; 28:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/43\">",
"      Keul R, Heinrich PC, M&uuml;ller-newen G, et al. A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 1998; 10:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/44\">",
"      Carrasco R, Smith JA, Lovell D. Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr Drugs 2004; 6:137.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration MedWatch. file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm175843.htm (Accessed on September 29, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/46\">",
"      Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012; 64:1263.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/bbs/topics/NEWS/2008/NEW01879.html (Accessed on November 23, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/48\">",
"      Tamilarasan KP, Kolluru GK, Rajaram M, et al. Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells. BMC Cell Biol 2006; 7:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/49\">",
"      Lehman TJ, Striegel KH, Onel KB. Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J Pediatr 2002; 140:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/50\">",
"      Lehman TJ, Schechter SJ, Sundel RP, et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. J Pediatr 2004; 145:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/51\">",
"      Wallace CA. The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum 1998; 41:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/52\">",
"      Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000; 43:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/53\">",
"      Ravelli A, Martini A. Methotrexate in juvenile idiopathic arthritis: answers and questions. J Rheumatol 2000; 27:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/54\">",
"      Reiff A, Shaham B, Wood BP, et al. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995; 13:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/55\">",
"      Foeldvari I, Wierk A. Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice. J Rheumatol 2010; 37:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/56\">",
"      Jahan A, Dewan V, Yadav TP. Leflunomide in systemic onset Juvenile idiopathic arthritis. Indian Pediatr 2012; 49:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/57\">",
"      Silverman E, Mouy R, Spiegel L, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005; 352:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/58\">",
"      Feito JG, Pereda CA. Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists. J Clin Rheumatol 2009; 15:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/59\">",
"      Wallace CA, Sherry DD. Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/60\">",
"      Savolainen HA. Chlorambucil in severe juvenile chronic arthritis: longterm followup with special reference to amyloidosis. J Rheumatol 1999; 26:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/61\">",
"      Palmer RG, Ansell BM. Acute leukaemia related to chlorambucil therapy for juvenile chronic arthritis. Clin Exp Rheumatol 1984; 2:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/62\">",
"      van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998; 41:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/63\">",
"      Emery HM. Treatment of juvenile rheumatoid arthritis. Curr Opin Rheumatol 1993; 5:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/64\">",
"      Silverman ED, Cawkwell GD, Lovell DJ, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol 1994; 21:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/65\">",
"      Uziel Y, Laxer RM, Schneider R, Silverman ED. Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a followup study. J Rheumatol 1996; 23:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/66\">",
"      Mouy R, Stephan JL, Pillet P, et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 1996; 129:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/67\">",
"      Ravelli A, De Benedetti F, Viola S, Martini A. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr 1996; 128:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/68\">",
"      Milanetti F, Abinun M, Voltarelli JC, Burt RK. Autologous hematopoietic stem cell transplantation for childhood autoimmune disease. Pediatr Clin North Am 2010; 57:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/69\">",
"      Tyndall A. Application of autologous stem cell transplantation in various adult and pediatric rheumatic diseases. Pediatr Res 2012; 71:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/70\">",
"      De Kleer IM, Brinkman DM, Ferster A, et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis 2004; 63:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/71\">",
"      Brinkman DM, de Kleer IM, ten Cate R, et al. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum 2007; 56:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/9/5274/abstract/72\">",
"      Daikeler T, Tichelli A, Passweg J. Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases. Pediatr Res 2012; 71:439.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6400 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-0B2EC3AACF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_9_5274=[""].join("\n");
var outline_f5_9_5274=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15850614\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15847691\">",
"      INITIAL THERAPY FOR MILD TO MODERATE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15847723\">",
"      THERAPY FOR REFRACTORY DISEASE/INITIAL THERAPY FOR SEVERE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15847756\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15849649\">",
"      Anticytokine therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3029185\">",
"      - IL-1 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12929729\">",
"      Anakinra",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12929736\">",
"      Canakinumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12929743\">",
"      Other IL-1 blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12929866\">",
"      - IL-6 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15849670\">",
"      - TNF-alpha inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15849688\">",
"      - Thalidomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33080326\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H272251835\">",
"      Leflunomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1645837\">",
"      B cell targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15850522\">",
"      Cytotoxic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15850595\">",
"      OTHER AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sulfasalazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hydroxychloroquine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9243469\">",
"      COMBINATION DRUG THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      HEMATOPOIETIC CELL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15850614\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35717?source=related_link\">",
"      Classification of juvenile arthritis (JRA/JIA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=related_link\">",
"      Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=related_link\">",
"      Pauciarticular onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17162?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39285?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Course, prognosis, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_9_5275="Risk factors for MRSA";
var content_f5_9_5275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for MRSA",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Recent hospitalization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Residence in a long-term care facility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent antibiotic therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Men who have sex with men",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Injection drug use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemodialysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incarceration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Military service",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sharing needles, razors, or other sharp objects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sharing sports equipment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged hospital stay",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_9_5275=[""].join("\n");
var outline_f5_9_5275=null;
var title_f5_9_5276="Chron neutrophilic leuk WHO";
var content_f5_9_5276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    WHO criteria: chronic neutrophilic leukemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Peripheral blood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        White blood cell count (WBC) &gt;25,000/microL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Segmented neutrophils and bands &gt;80 percent of WBCs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immature granulocytes (ie, promyelocytes, myelocytes, metamyelocytes &lt;10 percent of WBCs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myeloblasts &lt;1 percent of WBCs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No evidence for dysplasia in the granulocytic, erythrocytic cells, or platelets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monocytes &lt;1,000/microL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bone marrow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypercellular bone marrow biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neutrophilic granulocytes increased in percentage and number",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myeloblasts &lt;5 percent of nucleated marrow cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No dysplastic changes in the myeloid, erythroid, or megakaryocyte lineages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatosplenomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Philadelphia chromosome negative and BCR/ABL fusion gene negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No evidence for a myeloproliferative disorder (eg,",
"polycythemia vera, essential thrombocythemia, chronic idiopathic",
"myelofibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased neutrophil alkaline phosphatase score*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Not listed among the diagnostic criteria, but commonly found.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Imbert, M, et al. Chronic neutrophilic leukaemia. In: Jaffe, ES, Harris, NL, Stein, H, Vardiman, JW, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon 2001, p. 27. Permission granted from Harris, NL and Vardiman, JW.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_9_5276=[""].join("\n");
var outline_f5_9_5276=null;
var title_f5_9_5277="IgD mean by age";
var content_f5_9_5277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62882%7ERHEUM%2F53169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62882%7ERHEUM%2F53169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immunoglobulin D (IgD) normal and 95th percentile values by age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age (years)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Average normal IgD (mg/dL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Upper limit reference range IgD*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0-0.5",
"       </td>",
"       <td>",
"        0.07",
"       </td>",
"       <td>",
"        0.21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.5-1",
"       </td>",
"       <td>",
"        0.34",
"       </td>",
"       <td>",
"        1.64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-2",
"       </td>",
"       <td>",
"        0.71",
"       </td>",
"       <td>",
"        6.58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2-4",
"       </td>",
"       <td>",
"        1.60",
"       </td>",
"       <td>",
"        20.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4-6",
"       </td>",
"       <td>",
"        4.82",
"       </td>",
"       <td>",
"        29.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6-10",
"       </td>",
"       <td>",
"        4.49",
"       </td>",
"       <td>",
"        41.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10-15",
"       </td>",
"       <td>",
"        4.84",
"       </td>",
"       <td>",
"        23.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;15",
"       </td>",
"       <td>",
"        1.95",
"       </td>",
"       <td>",
"        23.7",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * &gt;2 standard deviations above the mean for age.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Haraldsson, A, Weemaes, CM, Jonasdottir, S, et al. Serum immunoglobulinD in infants and children. Scand J Immunol 2000; 51:415.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immunoglobulin A (IgA) normal values by age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Age",
"      </td>",
"      <td class=\"subtitle1\">",
"       Mean normal IgA &plusmn; range (mg/dL)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Percent of adult level &plusmn; range",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Newborn",
"      </td>",
"      <td>",
"       2 &plusmn; 3",
"      </td>",
"      <td>",
"       1 &plusmn; 2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1-3 months",
"      </td>",
"      <td>",
"       21 &plusmn; 13",
"      </td>",
"      <td>",
"       11 &plusmn; 7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4-6 months",
"      </td>",
"      <td>",
"       28 &plusmn; 18",
"      </td>",
"      <td>",
"       14 &plusmn; 9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7-12 months",
"      </td>",
"      <td>",
"       37 &plusmn; 18",
"      </td>",
"      <td>",
"       19 &plusmn; 9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       13-24 months",
"      </td>",
"      <td>",
"       50 &plusmn; 24",
"      </td>",
"      <td>",
"       25 &plusmn; 12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       25-36 months",
"      </td>",
"      <td>",
"       71 &plusmn; 37",
"      </td>",
"      <td>",
"       36 &plusmn; 19",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3-5 years",
"      </td>",
"      <td>",
"       93 &plusmn; 27",
"      </td>",
"      <td>",
"       47 &plusmn; 14",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6-8 years",
"      </td>",
"      <td>",
"       124 &plusmn; 45",
"      </td>",
"      <td>",
"       62 &plusmn; 23",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       9-11 years",
"      </td>",
"      <td>",
"       131 &plusmn; 60",
"      </td>",
"      <td>",
"       66 &plusmn; 30",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       12-16 years",
"      </td>",
"      <td>",
"       148 &plusmn; 63",
"      </td>",
"      <td>",
"       74 &plusmn; 32",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Adults",
"      </td>",
"      <td>",
"       200 &plusmn; 61",
"      </td>",
"      <td>",
"       100 &plusmn; 31",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Stiehm, ER, Fudenberg, HH. Pediatrics 1966; 37:715 and Stiehm, ER, Ochs, HD, Winkelstein, JA. Immunodeficiency Disorders: General Considerations. In: Immunologic Disorders in Infants and Children, 5th ed, Stiehm, ER, Ochs, HD, Winkelstein, JA (Eds), Elsevier Saunders, Philadelphia 2004, p. 307.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_9_5277=[""].join("\n");
var outline_f5_9_5277=null;
var title_f5_9_5278="Contents: General ID issues";
var content_f5_9_5278=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       General ID issues",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			General ID issues",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Fever",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/11/31927\">",
"           Approach to the adult with fever of unknown origin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/25/2456\">",
"           Drug fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/4/15431\">",
"           Etiologies of fever of unknown origin in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29098\">",
"           Fever and rash in the immunocompetent patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/10/8361\">",
"           Pathophysiology and treatment of fever in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/6/30825\">",
"           Clinical features and diagnosis of chronic fatigue syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/46/22247\">",
"           Identifying and managing casualties of biological terrorism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/42/11942\">",
"           Lymphangitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/21/4440\">",
"           Treatment of chronic fatigue syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infections in diabetes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/33/538\">",
"           Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/30/34278\">",
"           Emphysematous urinary tract infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/47/32502\">",
"           Susceptibility to infections in persons with diabetes mellitus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Microbiology laboratory",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/62/34791\">",
"           Approach to Gram stain and culture results in the microbiology laboratory",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/15/35059\">",
"           Microbiology specimen collection and transport",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Toxin mediated",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/36/37448\">",
"           Botulism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/52/5962\">",
"           Management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/26/42408\">",
"           Marine envenomations from corals, sea urchins, fish, or stingrays",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/41/19096\">",
"           Marine toxins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/44/31431\">",
"           Principles of snake bite management worldwide",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/11/7353\">",
"           Tetanus",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-E3A9199C34-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f5_9_5278=[""].join("\n");
var outline_f5_9_5278=null;
var title_f5_9_5279="Bench press";
var content_f5_9_5279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F57438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F57438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bench press",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 214px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient lies face up on the bench with the hands aligned with the shoulders while grasping the weight bar. The weight is lifted straight up and is then lowered to the chest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_9_5279=[""].join("\n");
var outline_f5_9_5279=null;
